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”I’ve missed more than 9000 shots in my career,
I’ve lost almost 300 games,
26 times, I’ve been trusted to take the game winning shot and missed.
I’ve failed over and over and over again in my life.
And that is why I succeed.”
Michael Jordan
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Abstract
Invasive techniques are essential in investigation and management of cardiac and vascular diseases,
particularly obstructive coronary artery disease. These invasive techniques can be performed for
diagnostic or interventional purposes, and the access to the target arteries can be done through the femoral
or the radial artery. The transradial approach may be clinically preferable, namely because its use has
been associated with fewer peri-procedural complications, like bleeding. Despite the advantages over
transfemoral approach, concerns have risen on the potential for transradial approach to increase the
incidence of peri-procedural neurological complications, like Stroke or Transient Ischemic Attack (TIA)
(Jurga et al., 2011). The aim of this work is to access the association between the risk of peri-procedural
Stroke/TIA and the transradial or the transfemoral approaches.
A propensity score analysis was performed in a sample of 16 710 patients included in a single
prospective registry between January of 2006 and November of 2012. Various PS methods like matching,
genetic matching, stratification and inverse probability of treatment weighting were used to estimate the
Average Treatment Effect for the Treated (ATT) and the Average Treatment Effect (ATE). To find the
best possible matching, PS estimates were fitted from a GAMs and from logistic regressions. A logistic
regression (LR) was performed too in order to identify all the factors associated to the occurrence of
peri-procedural Stroke/TIA and estimate the Odds Ratios. To handle the low number of events and the
subsequent separation problem, a Firth’s logistic regression correction was run.
Both Propensity Score analysis and regression methods reached the same conclusions. The use of
Transradial or Transfemoral Approach does not impact the occurrence of peri-procedural Stroke/TIA.
So the clinically preferential use of Transradial can be performed without concerns relative to this
technique. Regarding the methodology, GAM PS estimates provide better matchings when there are
variables non-linear related with the treatment assignment logit, but genetic matching can overcome these
differences by matching individually on these variables through the Generalized Mahalanobis Distance.
Keywords: Propensity Score, Generalized Additive Models, Genetic Matching, Stratification, Inverse
Probability of Treatment Weighting
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Resumo
A doenc¸a corona´ria e´ uma das principais causas de morbilidade e mortalidade a` escala global quer nos
no mundo moderno quer nos paı´ses em desenvolvimento devido ao estilo de vida das populac¸o˜es e ao
progressivo envelhecimento da populac¸a˜o. Os principais fatores de risco sa˜o a hipertensa˜o arterial, a
dislipide´mia, a diabetes, o tabagismo e o sedentarismo (Sacco et al., 1997; Donnan et al., 2008). As
manifestac¸o˜es clı´nicas dependem largamente do territo´rio vascular afectado.
Uma variedade de te´cnicas invasivas e´ utilizada em cardiologia, nomeadamente para o diagno´stico
e tratamento e da doenc¸a corona´ria obstrutiva. Por norma, estes procedimentos usam um
cate´ter (essencialmente um ”tubo” inserido atrave´s de um ponto de acesso e guiado ao local de
diagno´stico/intervenc¸a˜o, de modo a executar o procedimento). O ponto de acesso pelo qual o cate´ter
e´ inserido e´ em geral a arte´ria femoral ou a arte´ria radial. Uma das complicac¸o˜es mais temidas da
manipulac¸a˜o endovascular associada a este tipo de procedimentos e´ o Acidente Vascular Cerebral (AVC).
A obstruc¸a˜o das arte´rias intra-craneanas devido a feno´menos trombo-embo´licos provoca isque´mia cerebral
e em u´ltima ana´lise, morte celular com perda tempora´ria e definitiva de func¸a˜o neutolo´gica (por exemplo,
dificuldade na fala, dificuldade em compreender outras pessoas, perda de visa˜o e falta de capacidade em
sentir e mover certas partes do corpo) (Donnan et al., 2008).
Durante grande parte do se´culo XX, o acesso transfemoral foi o mais utilzado pela maior parte
dos cardiologistas de intervenc¸a˜o. Recentemente, tem sido demonstrado que o acesso transradial se
associa a menos complicac¸o˜es peri-procedimento, como por exemplo a hemorragia, menos morbilidade e
mortalidade, e tem menos custos que o acesso femoral. Todas estas vantagens contribuı´ram para a grande
expansa˜o do uso da arte´ria radial como ponto de acesso (Nathan and Rao, 2012; Burzotta et al., 2013).
No entanto, surgiram preocupac¸o˜es relativamente ao acesso transradial e ao risco de complicac¸o˜es
neurolo´gicas, sobretudo devido a` maior manipulac¸a˜o do arco ao´rtico e das arte´rias subcla´vias (Jurga
et al., 2011). O grande objetivo deste trabalho e´ estudar a associac¸a˜o entre a ocorreˆncia de complicac¸o˜es
neurolo´gicas e o tipo de acesso usado durante o procedimento.
Os dados usados neste estudo observacional foram recolhidos a partir de cateterismos diagno´sticos e
de intervenc¸a˜o realizadas no Hospital de Santa Cruz, Carnaxide, entre Janeiro de 2006 e Novembro de
2012, sendo que os indivı´duos incluı´dos no estudo teˆm 18 anos de idade, ou mais, tendo sido sujeitos a
manipulac¸a˜o da arte´ria aorta ascendente ou do arco ao´rtico. A populac¸a˜o final do estudo compreende
16710 indı´viduos.
A primeira abordagem executada para estudar esta associac¸a˜o foi a regressa˜o logı´stica pois e´ a
abordagem mais usada e considerada ”standard”. Para uma correta aplicac¸a˜o desta metodologia e´
conveniente ter 10 eventos por cada varia´vel registada, para que assim os resultados sejam fia´veis (Peduzzi
et al., 1996). No entanto, neste estudo apenas temos 27 eventos para 25 varia´veis, o que po˜e em causa a
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utilizac¸a˜o da regressa˜o logı´stica. Este nu´mero baixo de eventos origina o problema da Separac¸a˜o, no qual
na˜o e´ possı´vel calcular a real contribuic¸a˜o das varia´veis ”Transplante Renal” e ”Histo´rico de AVC/AIT”
na ocorreˆncia do desfecho. Para contornar este problema, optou-se que pela aplicac¸a˜o da regressa˜o
logı´stica de Firth, em que a estimac¸a˜o de ma´xima verosimilhanc¸a tem por base uma verosimilhanc¸a
penalizada (Firth, 1993).
O baixo nu´mero de eventos e o grande nu´mero de varia´veis a controlar (como e´ o caso) foi a
principal motivac¸a˜o para a utilizac¸a˜o da metodologia assente em Propensity Scores, ale´m de outras
vantagens referidas neste trabalho. O Propensity Score (PS) de cada individuo e´, neste caso, a sua
probabilidade de ter sido intervencionado pelo acesso transradial, sabendo determinado conjunto de
varia´veis. Tradicionalmente, os PS sa˜o calculados usando uma regressa˜o logı´stica. O ca´lculo destes pela
regressa˜o logı´stica pressupo˜e que existe uma relac¸a˜o linear entre o logit da varia´vel dependente (Acesso
Transradial) e as covaria´veis, pelo que, se este pressuposto na˜o for verdadeiro, as estimativas dos PS esta˜o
erradas. Neste estudo, os PS tambe´m va˜o ser calculados via modelos aditivos generalizados (GAMs), pois
este tipo de modelos sa˜o mais flexı´veis e, portanto, conseguem descrever mais eficazmente a real relac¸a˜o
entre uma covaria´vel e a varia´vel dependente, originando estimativas dos PS mais fia´veis (Woo et al., 2008).
A primeira metodologia de Propensity Scores usada e´ o ”Matching”, a qual consiste em emparelhar
indivı´duos que foram intervencionados pelo acesso transradial com outros intervencionados pelo
acesso transfemoral. O ”Matching” emparelha ı´ndividuos com PS semelhantes. Isto porque, esta´
provado que dois indivı´duos sa˜o assintoticamente compara´veis (mesma distribuic¸a˜o de varia´veis) se
tiverem PS estimados semelhantes (Rubin and Rosenbaum, 1983). Va´rios emparelhamentos foram
executados, diferindo na forma de serem estimados os PS (usando a regressa˜o logı´stica ou modelos
aditivos generalizados), ou diferindo nos conjuntos de varia´veis usados como covaria´veis nos modelos.
Ale´m do ”Matching” simples, tambe´m foi executado o ”Matching” gene´tico, que utiliza a distaˆncia de
Mahalanobis (distaˆncia multivariada) como medida de emparelhamento. Esta distaˆncia e´ calculada a
partir das varia´veis observadas durante o estudo e dos PS estimados. No ”Matching” gene´tico tambe´m
foram experimentados va´rios conjuntos de varia´veis, e os dois me´todos de regressa˜o para estimar
PS. No final, o melhor ”Matching” conseguido (de entre os ”Matchings” simples e gene´ticos) foi um
emparelhamento gene´tico o qual incluiu todas as varia´veis observadas e PS estimados a partir de um
GAM. A qualidade do emparelhamento e´ medida atrave´s do qua˜o homoge´neas sa˜o as distribuic¸o˜es das
varia´veis nos dois grupos a comparar. O emparelhamento escolhido possibilitou a criac¸a˜o de dois grupos
de tratamento homoge´neos relativamente a`s distribuic¸o˜es das varia´veis, e assim foi possı´vel calcular o
”Average Treatment Effect for the Treated (ATT)”. Tambe´m se provou que os PS ajustados a partir de
GAMs originam melhores emparelhamentos, em termos gerais, como sugere a literatura (Woo et al., 2008).
Outra metodologia baseada em Propensity Scores usada foi a Estratificac¸a˜o. Aqui, tomando partido
dos Propensity Scores ajustados a partir de GAMs com todas as varia´veis registadas como dependentes,
agrupou-se os indivı´duos em 5 estratos. Dentro de cada estrato, os indı´viduos sa˜o semelhantes
relativamente ao PS e, consequentemente, semelhantes em relac¸a˜o a` distribuic¸a˜o das varia´veis, pelo que
assim e´ possı´vel calcular o ”Average Treatment Effect (ATE)” (Rosenbaum and Rubin, 1984). Outro
modo usado para calcular o ATE, foi pela metodologia de ”Inverse Probability of Treatment Assignment
(IPTW)”. O IPTW consiste em atribuir um peso a cada indivı´duo, sendo cada peso calculado com base
no PS de cada indivı´duo. A soma dos pesos em cada grupo de tratamento e´ igual. Este procedimento
cria duas amostras sinte´ticas com a mesma dimensa˜o, que sa˜o diretamente compara´veis, na˜o levantando
quaisquer problemas relativos a um possı´vel confundimento (Austin, 2011a).
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Ambos os me´todos de regressa˜o e as metodologias usando PS, retornaram as mesmas concluso˜es.
O uso do acesso transradial ou transfemoral na˜o influencia a ocorreˆncia de complicac¸o˜es neurolo´gicas
peri-procedimento. Assim, o uso clinicamente preferencial do acesso transradial pode continuar a ser
aplicado sem preocupac¸o˜es de maior. Estas concluso˜es reforc¸am a literatura (Raposo et al., 2015).
Palavras-Chave: Propensity Score, Modelos Aditivos Generalizados, Matching Gene´tico,
Estratificac¸a˜o, Inverse Probability of Treatment Weighting
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Chapter 1
Introduction
1.1 The Problem
In cardiology, the radial artery has recently been used with increasing frequency as the preferential
vascular access both in diagnostic and interventional procedures. This so called transradial approach has
risen some concerns relative to the higher risk of peri-procedural neurologic complications like Stroke
and TIA (Raposo et al., 2015). In this work, the association between this approach and possible further
neurologic complications is studied.
1.1.1 Coronary Artery Disease
One of the main reasons persons are subjected to invasive techniques, involving the manipulation of
the ascending aorta and subclavian arteries, is the Coronary Artery Disease. Also known as ischemic
heart disease, it is characterized by the shortage of blood flow to the heart provoking damage to it (e.g.
Myocardial Infarction(MI)). The underlying mechanism responsible for this involves atherosclerosis of
the arteries of the heart. Atherosclerosis is the process responsible for the thickening of artery walls due
to accumulation of white blood cells and remnants of dead cells including cholesterol and triglycerides.
This provokes narrowing and loss of elasticity of the artery walls, impairing the blood flow (Figure
1.1)(National Heart and Institute, 2016). The main risk factors are high blood pressure, dyslipidemia
(abnormal amount of lipids in the blood), smoking, diabetes, lack of exercise, poor diet and alcohol
consumption. Peripheral artery disease (PAD) is an analogue disease, concerning only the narrowing of
arteries that are not coronary (Mendis; Shanthi et al., 2011).
Figure 1.1: Example of a narrowed artery due to atherosclerosis. Taken from: Blausen Medical Communications, Inc.
1.1.2 Stroke and Transient Ischemic Attack
Stroke, also known as cerebrovascular accident (CVA) is a consequence of poor blood flow to the brain
resulting in cell death, affecting the regular brain functioning. When a stroke occurs, the most common
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signs are inability to move or feel parts of the body, difficulties in speaking and understanding and partial
loss of vision. If these symptoms last only for a few hours it is known as a Transient Ischemic Attack
(TIA), otherwise it is a Stroke. The consequences of Stroke or TIA can be permanent. The main risk
factors are high blood pressure, smoking, obesity, high blood cholestrol and diabetes mellitus . Typically,
the two main causes of CVA are the blockage of an artery and cerebral bleeding (Donnan et al., 2008).
In the context of this work, the study endpoint will be the Stroke or TIA provoked by the manipulation
unavoidably associated with invasive procedures.
1.1.3 Diagnostic and Interventional Procedures
As stated before, the cardiac procedures, may have diagnostic or interventional purposes. The need for
catheterization is common to both situations. A catheter is an device which is guided through the vascular
access point to the coronary arteries and can be used to perform a wide range of procedures. The entrance
site of the catheter is usually the radial (Transradial Approach) or the femoral artery (Transfemoral
Approach) (Figure 1.4). An overview through the most common invasive interventional and diagnostic
procedures is presented.
1.1.3.1 Diagnostic Procedures
Angiography The most common diagnostic procedure. Angiography is a medical imaging technique
used to get images from the heart chambers, arteries or veins. This is performed by injecting a dose of
contrast volume and then, by applying X-ray techniques like Fluoroscopy, obtaining a view of a given
anatomical structure’s morphology, trough opacification of its lumen. A depiction of angiography is
displayed in Figure 1.2 (Topol and Teirstein, 2016).
Figure 1.2: Angiography through the femoral artery depicted. Taken from: Blausen Medical Communications, Inc.
Catheters can also be used to guide other diagnostic devices, like for example intravascular ultrasound
probes, pressure and/or flow sensor-tipped guide wires.
1.1.3.2 Interventional Procedures
Many interventional procedures are performed percutaneously. Angioplasty, also known as Percutaneous
Coronary Intervention (PCI), is by far the most common. In this procedure the main objective is to widen
the obstructed arteries (or veins). Here, the catheter has a collapsed balloon at its tip, and when it reaches
the obstructed localtion, the balloon is inflated by the operator and pushes back the artery walls and its
plaques widening them (Figure 1.3). This improves the blood flow as pretended. Balloons can also be
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used to dilate stenotic valves (balloon valvuloplasty) and to implant stents (Topol and Teirstein, 2016).
Figure 1.3: Angioplasty depicted. A: Catheter with the balloon collapsed. B: Catheter with the balloon inflated. C: Widened
artery.
A stent is a metal or polymeric ”tube” used to keep an artery widened. Stenting is an upgrade
to plain-balloon angioplasty and increases both its safety and efficacy in many clinically important
situations. Coronary angioplasty with stenting is widely used and over the years it has replaced Coronary
Artery Bypass Grafting (CABG) - a surgical procedure - in many patients warranting myocardial
revasculzarization (Topol and Teirstein, 2016).
1.2 State of the Art
Many forms of cardiac and vascular disease that may need invasive techniques to be managed, particularly,
obstructive coronary artery disease. These invasive techniques can have therapeutic or merely diagnostic
purposes. In both situations, there is the need of an arterial access to perform the procedure. During the
second half of the 20th century, various forms of arterial access were developed like the access through
the radial, ulnar, sub-clavian and femoral arteries, performed using the percutaneous Seldinger technique
or direct surgical exposure (Bourassa, 2005). Until recent years, the Transfemoral Approach (procedure
that uses the femoral artery as access point) was the preferred one by interventional cardiologists due to
the high compatibility with the Seldinger puncture technique and due to the large calibre of the vessel
allowing various sheaths. Although Transfemoral Approach gained great popularity, it has been proved
that this approach causes many peri-procedural complications like bleeding, and therefore is responsible
for longer admission times and higher morbidity and mortality (Nathan and Rao, 2012; Burzotta et al.,
2013).
The anatomic characteristics of the radial artery make it a great access point for many procedures (not
only cardiac), e.g. it is accessible in the anterior aspect of the forearm, the vessel calibre is large enough
and vascular complications are rare (Bhat et al., 2012) (Figure 1.4). Many studies have pointed that
Transradial Approach has many benefits in diverse clinical settings like reduced mortality, particularly,
in the group of patients with acute coronary syndromes, in whom bleeding can nullify the benefits of
the procedure itself (Nathan and Rao, 2012). In addtion, Transradial Approach is less expensive (early
and mid-term) (Mitchell et al., 2012). Improvements in access materials and catheters dedicated to this
technique have contributed to the wide spread of radial artery as access point. This choice do not impact
the overall procedure performance (Dangoisse et al., 2013).
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(c)
Figure 1.4: (a) Radial Artery depicted (right arm). (b) Femoral Artery depicted (right leg). (c) Schematic of the coronary arteries
(around the heart). Taken from: Anatomy of the Human Body (Gray, 2000)
These access points (radial and femoral) can impact the way ascending aorta and subclavian arteries
(specially the right brachiocephalic artery) are manipulated (Figure 1.4). Because of this, there are
concerns regarding the potentially increased risk of cerebral embolization. Recently, a significantly higher
rate of micro-embolization within a subset of patients undergoing Transradial Approach has been reported
(Jurga et al., 2011). However, these findings have not been confirmed in a large multicenter registry (Ratib
et al., 2013b). Due to the low number of peri-procedural Strokes/Transient Ischemic Attacks (TIA), it is
very difficult to design and perform powered studies, in order to identify significant differences regarding
this important endpoint.
In 2015, Raposo et al reported that there were no increased risk of peri-procedural Stroke/TIA by
undergoing catheterization through the radial artery. This work uses this very same data and tries to extend
the previous work by applying other type of PS methodologies.
1.3 Objectives
The objective of this study is to study the association between the vascular access used (arterial or femoral
artery) in a cardiac procedure and the occurrence of peri-procedural neurological complications (Stroke or
Transient Ischemic Attack). This association is to be studied by regression methods (logistic regression)
and Propensity Score Analysis (Matching, Genetic Matching, Stratification and IPTW).
1.4 Work Overview
Chapter 1 is a brief introduction to the problem. This includes several medical explanations about the
problem, the state-of-the-art, the objectives and why this work is important. In Chapter 2, it is explained
how the study was designed, the variable description, the sample baseline characteristics and the definition
of the study outcome. In Chapter 3, all the statistical methodologies employed are described in detail,
namely, Generalized Linear Models, Generalized Additive Models, the Propensity Scores properties
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and its applications like Matching, Stratification and IPTW. The results of the application of these
methodologies to the data are reported in Chapter 4. The results are discussed in Chapter 5, and Chapter 6
contains the final Conclusions regarding the problem risen in Chapter 1.
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Chapter 2
Study Design
2.1 Observational Study
The main objective of observational studies is to establish causality between the hypothetical cause (in
clinical research, commonly described as ”treatment” or ”exposure”), and the effect. Usually, there are
two groups in study, the control and the treatment group, which differ only in the treatment assigned. The
main objective of a study is to prove that the outcome difference between groups is caused by the type of
treatment received (Gordis, 2014). In an observational study, the treatment assignment is not randomized,
consisting on extracting knowledge from databases already established.
2.2 Data Source and Entry Criteria
This observational study was performed using data from the Angiography and Cardiovascular
InteRventiOn centre at Santa Cruz HoSpital (ACROSS) Registry. The database (Cardiobase R©,
Infortucano R©, Lisbon, Portugal) has records regarding anthropometric, demographic, clinical and
procedure related variables. Initially, all subjects who were exposed to invasive procedures involving an
arterial vascular access, during January’2006 until November’2012, were screened (n=19,961). The entry
criteria were the following:
• age higher or equal than 18 years old;
• being subjected to interventional or diagnostic procedures involving any manipulation of the
ascending aorta or the aortic arch.
The final study population size is 16,710 patients.
Radial Artery was used as primary vascular access site in 4,195 cases (25% of the sample) and in 36
additional patients after conversion from femoral-to-radial. Thus, the final transradial group size is 4,231.
2.3 Variables
2.3.1 Variables Description
Variables Description for each recorded variable is displayed in Table 2.1:
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Table 2.1: Name, Support and Description for each recorded variable.
Variable Support Description
Demographic
Age (years) {18,19, 20,. . .} Age in years
Male Gender {0,1} 1:Male 0:Female
Body Mass Index (BMI) (Kg/m2) (0,+∞) The body mass index value
Cardiovascular Risk Factors
Diabetes mellitus {0,1} 1:Has Diabetes mellitus 0:Do not have
Diabetes mellitus
Hypertension {0,1} 1:Has Hipertension 0:Do not have
Hypertension
Smoking (current or former) {0,1} 1:Was/Is a smoker 0:No smoking
history
Dyslipidemia {0,1} 1:Has Dyslipidemia 0:Do not have
Dyslipidemia
Prior Clinical History
Myocardial Infarction (MI) {0,1} 1:MI history 0:No MI history
Percutaneous Coronary Intervention (PCI) {0,1} 1:PCI history 0:No PCI history
Coronary Artery Bypass Surgery (CABG) {0,1} 1:CABG history 0:No CABG history
Peripheral Artery Disease (PAD) {0,1} 1:PAD history 0:No PAD history
Stroke/Transient Ischemic Attack (TIA) {0,1} 1:Stroke/TIA history 0:No Stroke/TIA
history
Non-CABG Surgery {0,1} 1: Non-CABG Surgery History 0: No
Non-CABG Surgery History
Moderate/severe Chronic Renal Disease (CRD) {0,1} 1:CRD history 0:No CRD history
Renal Transplant {0,1} 1:Renal Transplant history 0:No Renal
Transplant history
Clinical Setting
and Procedural Characteristics
Interventional Procedure {0,1} 1:Angioplasty/Percutaneous coronary
intervention 0:Cardiac catheterization
for diagnostic purposes
Acute Coronary Syndrome {0,1} 1:Has Acute Coronary Syndrome 0:Do
not have Acute Coronary Syndrome
Aortic Valvulopathy {0,1} 1: Has Aortic Valvulopathy 0: Do not
have Aortic Valvulopathy
Systolic Blood Pressure (SBP) (mmHg) (0,+∞) The SBP value in mercury milimeters
(mmHg)
Diastolic Blood Pressure (DBP) (mmHg) (0,+∞) The DBP value in mercury milimeters
(mmHg)
Coronary artery disease extension {0,1,2,. . .} Number of vessels with stenosis*
Number of treated segments {0,1,2,. . .} Number of vessels treated. Only refers
to patients intervened with angioplasty
Fluoroscopy time (min) (0,+∞) The Fluoroscopy** duration in minutes
Contrast Volume (mL) {0,1,2,. . .} The quantity of contrast used during
fluoroscopy in milliliters
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Number of Catheters Used {0,1,2,. . .} The number of Catheters used during
the procedure
* abnormal narrowing in a blood vessel or other tubular organ or structure.
** imaging technique used during procedure.
2.3.2 Sample Baseline Characteristics
The sample in study is, on average, 65.79 years old, is predominantly male (67%), 28% is diabetic, 73%
is hypertensive, 40% is/was a smoker and 60% has dyslipidemia. More Sample Baseline characteristics
are summarized in Table 2.2.
Table 2.2: Sample Baseline Characteristics. Percentage (%) for categorical variables and Average ± Standard Deviation (SD) for
continuous variables.
Variable
Demographic
Age (years) [average ± SD] 65.79 ± 11.59
Male Gender (n, %) 11 134 (67%)
BMI (Kg/m2) [average± SD] 27.35 ± 4.04
Cardiovascular Risk Factors
Diabetes mellitus (n, %) 4 703 (28%)
Hypertension (n, %) 12 211 (73%)
Smoking (current or former) (n, %) 6 601 (40%)
Dyslipidemia (n, %) 10 039 (60%)
Prior Clinical History
MI (n, %) 3 569 (21%)
PCI (n, %) 3 930 (24%)
CABG (n, %) 1 537 (9%)
Stroke/TIA (n, %) 10 284 (8%)
PAD (n, %) 1 112 (7%)
Non-CABG Surgery (n, %) 425 (3%)
Moderate/severe CRD (n, %) 531 (3%)
Renal Transplant (n, %) 70 (0,4%)
Clinical Setting and Procedural Characteristics
Interventional Procedure (n, %) 6 973 (42%)
Acute Coronary Syndrome (n, %) 6 204 (37%)
Aortic Valvulophaty (n, %) 1 220 (7%)
SBP (mmHg) [average± SD] 139.15 ± 28.16
DBP (mmHg) [average± SD] 72.27 ± 13.05
Coronary artery disease extension [average± SD] 1.35 ± 1.14
Number of Treated Segments [average± SD] 1.35 ± 1.15
Fluorosopy time (min) [average± SD] 9.21 ± 0.25
Contrast Volume (ml) [average± SD] 136.65 ± 95.60
Number of Catheters Used [average± SD] 2.80 ± 1.36
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2.3.3 Definition of Study Outcome
The study outcome was defined as the occurrence of clinically significant stroke or transient ischemic
attack (TIA) related to endovascular manipulation. At the hospital, all cases suspected of neurological
complications are submitted to brain imaging and recorded in the hospital database. In order to identify
possible Stroke/TIA related to the procedure, it was created a shortlist of patients who underwent both
endovascular manipulation and brain imaging. Then, each one of the cases on the shortlist were reviewed,
preferably by a neurologist, to access if the Stroke/TIA was due to the procedure. These confirmed
cases had to occur within 48 hours of the procedure, and had to be unrelated to coronary artery bypass
grafting. For patients discharged or transferred to other hospitals within this 48 hour period, their data
was registered in the database: Cardiobase R©, Infortucano, Lisbon, Portugal.
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Chapter 3
Methodology
3.1 Generalized Linear Models
3.1.1 Introduction
A regression analysis is a way to access the relationship between different independent variables(X1,X2, ...,Xk) and a variable of interest Y . A generalized linear model (GLM) is an extension
of the linear classic model Y = β0 + β1X1 + ⋅ ⋅ ⋅ + βkXk + ,  ∩N(0, σ2), where each βj (j = 1, ..., k)
express the contribution of each variable to the value of Y (Amaral Turkman and Loiola Silva, 2000).
g(µ) = β0 + β1X1 + ⋅ ⋅ ⋅ + βkXk (3.1)
A GLM is a regression model where Y belongs to the exponential family, and a linear structure(β0 + β1X1 + ⋅ ⋅ ⋅ + βkXk) is related to E(Y ∣X) = µ by a link function g(⋅) as in Equation 3.1. The
link function used depends, mostly, on the Y response type. In Table 3.1 are described some link functions:
Table 3.1: Link Common distributions with typical uses
Distribution of Y Support of distribution Link Name Link Function(g(µ))
Normal real(−∞,+∞) identity µ
Exponential or Gamma real(0,+∞) inverse −µ−1
Poisson integer (0,1,2, . . . ,+∞) log ln(µ)
Bernoulli integer {0,1} logit ln( µ1−µ)
Suppose Y is a binary dependent variable and X = (X1,X2,X3, ...,Xk) the independent variables
that may be asssociated with Y . So, for each subject i, these are the observations: (yi, xi1, xi2, xi3, ..., xik).
Formalizing, Yi ⌢ Bernoulli(pi), µi = E(Yi∣xi = (xi1, xi2, . . . , xik)) = pi = Pr(Yi = 1∣xi), i = 1,2...n.
Thus, the appropriate link function is the logit because µˆ will always fall within 0 and 1. The
GLM regression that uses the logit link, it is called Logistic Regression (LR) and it is represented this way:
pi = exp(β0 + β1x1i + ... + βkxki)
1 + exp(β0 + β1x1i + ... + βkxki)
ln( pi
1 − pi ) = β0 + β1x1i + ... + βkxki
(3.2)
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3.1.2 Estimation
The main objective of LR is to estimate the contribution of each variable X for the final outcome and,
therefore, every pi. By the maximum-likelihood estimation method, it is possible to estimate the β
coefficients.
The Maximum-Likelihood Estimation (MLE) method finds the β = (β1, β2, ..., βk) values, which
maximize the log-likelihood function:
l = lnL(y,β) = ln n∏
i=1P (Yi = yi∣Xi = xi) = ln
n∏
i=1 p
yi
i (1 − pi)1−yi = n∑
i=1 ln(pyii (1 − pi)1−yi)= n∑
i=1 li =
n∑
i=1[yi(β0 + β1x1i + ... + βkxki) − ln(1 + (β0 + β1x1i + ... + βkxki))]
(3.3)
In order to maximize it:
∂l
∂β
= 0⇔ U(β) = 0⇔
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎣
U(β0)
U(β1)⋮
U(βk)
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎦
= 0 (3.4)
U(βj) = ∂l
∂βj
= n∑
i=1
∂li
∂pi
pi
βj
= n∑
i=1
yi − pi
pi(1 − pi)xjipi(1 − pi) = n∑i=1xji(yi − pi) (3.5)
The β parameters that maximize the log-likelihood function, are the ones where U(β) = 0 (3.4).
Since there is no analytical solution for this equation, an interative method like Newton-Raphson (NR) is
required.
Let X =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 x11 x12 x13 . . . x1k
1 x21 x22 x23 . . . x2k
1 ⋮ ⋮ ⋮ ⋱ ⋮
1 xn1 xn2 xn3 . . . xnk
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎦
, Y =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎣
y1
y2⋮
yn
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎦
, p =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎣
p1
p2⋮
pn
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎦
,
so U(β) = U = XT (Y-p). In order to find the β parameters where U(β) = 0, the NR iterative method is
applied till convergence is obtained:
βˆm+1 = βˆm + [−∂U∂β ]−1(βˆm)U(βˆm)
βˆm+1 = βˆm + (XTWX)−1(βˆm)XT (Y-p)(βˆm)
, (3.6)
where W =Diag(p(1 − p))
Odds Ratio(OR) is a conditional effect and it is one of the most used risk measures in clinical research.
The OR is the ratio between the odds of an ”exposed” subject i ( pi1−pi ) and the odds of a ”non-exposed”
subject j ( pj1−pj ), holding all the other variables constant. Suppose, for two subjects i and j, xi2 = xj2,
xi3 = xj3, . . . , xik = xjk and xi1 − xj2 = 1. In this case, the subject i is the one being ”exposed” to the
risk factor X1. So, assuming a logistic model, the odds ratio is given by eβ1 . This is proved here:
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log( pi
1 − pi ) − log( pj1 − pj ) = (β0 + β1xi1 + β2xi2 + ⋅ ⋅ ⋅ + βkxik) − (β0 + β1xj1 + β2xj2 + ⋅ ⋅ ⋅ + βkxjk)
log( pi1−pipj
1−pj ) = (β0 − β0) + (β1xi1 − β1xj1) + (β2xi2 − β2xj2) + ⋅ ⋅ ⋅ + (βkxik − βkxjk)
log(OR) = β1(xi1 − xj1)
OR = eβ1
(3.7)
3.1.3 Hypothesis Tests and Model Selection
Wald Test: This test is used to test, for example, H0 ∶ βj = 0 vs H1 ∶ βj ≠ 0 (j=1,...,k). The covariance
matrix of βˆ is : Cov(βˆ) = (XTWX)−1, so the standard deviation of βˆj is sd(βˆj) = √(XTWX)−1(j+1,j+1).
As βˆj−βj
sd(βˆj) ∼ N(0,1), it is possible to make inferences about the β values.
Likelihood-ratio test: In order to compare the goodness-of-fit of 2 models, the Likelihood-ratio test
is performed. This test evaluates if the data is more likely under one model or another.
Assume a logistic model adjusted for k variables (Mk), and another one adjusted for the same k
variables plus 1 (Mk+1). In this case, the likelihood ratio is λ = L(Mk)L(Mk+1) . The model with more variables
(Mk+1) will always fit at least as well, i.e., have a greater or equal likelihood, than the model with less
variables (Mk), so log(λ) < 0. Mk+1 has n-(k+1)-1 free parameters, while Mk has n-k-1 free parameters
Formalizing the hypothesis, H0 ∶ β = (β0, β1, . . . , βk) vs H1 ∶ β = (β0, β1, . . . , βk, βk+1). As−2log(λ) ∼ χ2(n−k−1)−(n−(k+1)−1), the significance is calculated this way. If there is no statistical
difference between the models (H0 is not rejected), the model with less parameters is the chosen one.
Other statistical tests can be used like the Score test.
Aikaike’s Information Criterion (AIC): AIC measures the relative quality of a model in comparison
with other models, given the same dataset. This measure estimates the information lost by the model
representation of the data. So a better model will have a lower AIC. The big question here is: In order to
get a better adjustment, Is the complexity of the model worth? If two models have the same likelihood,
given the same dataset, the one with less AIC will be the one with less variables. Inversely, between two
models with the same number of variables, the one with less AIC is the one with a higher likelihood.
Basically, this measure deals with the compromise between few variables and a great likelihood. AIC is
defined in Equation 3.8:
AIC = 2k − 2ln(L) (3.8)
where k is the number of variables and L the model’s likelihood.
3.1.4 The Separation Problem and Firth’s LR correction
The Separation Problem When few events occur in a dataset (Y=1), there is great risk of facing the
”separation” or the ”monotone likelihood” problem . This kind of problem arises when the predictor (or a
linear combination of some subset of the predictors) is associated with only one outcome value (highly
predictive). For example, if the predictor X is dichotomous, and the outcome y = 1 for all observed x
= 1, and y=0 for all x=0, the condition ”complete separation” is said to be obtained. If the outcome
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y=1 for all observed x=1, but there are different outcomes values (y=0 and y=1) for x=0, it is called a
”quasi-separation” situation (Table 3.2).
Table 3.2: Two examples of Complete Separation (left) and Quasi-Separation (right), for a sample size=20000 with 25 events. X
is the predictor and Y the outcome.
Y
0 1
X
0 19975 0
1 0 25
Y
0 1
X
0 15000 0
1 4975 25
This separation situations cause problems estimating the coefficients, using the MLE. In a complete
separation context, the β estimates tend to be infinite because the MLE, continuously, maximizes the
likelihood. In a quasi-separation, the β estimates are not infinite but are very large, with huge standard
errors. Of course, these estimates are not correct and do not reflect the real effect of X. As the β s.e.
are large, the Wald’s test always returns non-significant statistics. And, the Likelihood Ratio test is not
trustworthy as well because the estimated likelihood cannot be taken seriously. To mitigate this problem,
a penalized MLE was developed by Firth in 1993 (Firth, 1993).
Firth’s Logistic Regression estimation algorithm
In order to reduce this small sample bias, Firth suggested to maximize a penalized maximum
likelihood instead:
L(β)∗ = L(β)∣I(β)∣1/2
logL(β)∗ = logL(β) + 1/2log∣I(β)∣ (3.9)
being I(β) = E [( ∂∂β log(f(X;β)))2∣β] the information matrix at β. So the score function is:
U(βj)∗ = ∂logL(β)∗
∂βj
(j = 1, . . . , k)
U(βj)∗ ≡ U(βj) + 1/2 trace[I(β)−1{∂I(β)/∂βj}]
U(βj)∗ = n∑
i=1{yi − pi + hi(1/2 − pi)}xir = 0
(3.10)
being hi the ith diagonal elements of matrix H = W 1/2X(XTWX)−1XTW 1/2. As U(β) has no
analytical solution, the estimates are obtained iteratively until convergence:
β(m+1) = βm + I−1(β(m))U(β(m))∗ (3.11)
In this context, the β confidence intervals (CI) are not estimated based on Cov(βˆ), but based on each β
profile likelihood. Although the Wald’s Test is possible under these circumstances, the Likelihood Ratio
test is the test usually used to check if one variable holds within the model. For further information about
this method consult Heinze and Schemper’s article ”A solution to the problem of Separation in Logistic
Regression” (Heinze and Schemper, 2002).
3.1.5 Minimum p-value approach
In clinical context, often, there is the need to categorize variables in order to improve decision making. For
example, if a variable is categorized, it is much easier to make treatment recommendations, determining
study eligibility or to balance treatment groups in a clinical trial. (Mazumdar and Glassman, 2000)
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Table 3.3: Contingency table for cutpoint c
Y
0 1
X ≤ c n11 n12
X > c n21 n22
In order to find the cutpoint that best categorize some variable, the minimum p-value approach
was developed. The best cutpoint (if defining two groups) is the one that creates the most different
groups regarding their risk of suffering the outcome (Y). This is accessed by finding the cutpoint c that
produces the minimum p-value when performing a chi-squared test (Table 3.3). The higher the dependence
between the categorized and the outcome variable, the more meaningful risk differences exist between the
categorized groups.
A categorized variable can be significant while its respective continuous analog is not. This means that
categorization widens the range of possible variables to be included in a model (Mazumdar and Glassman,
2000).
3.1.6 Predictive Power
Hosmer-Lemeshow Test: This comparison is done within subgroups of the model population. The
groups are, typically, defined by the deciles of the fitted values of the model. Consider G the number of
groups, Og the number of observed events in group g, Eg the number of expected events in group g, Ng
the number of subjects in group g and pig the predicted risk for the group g. Under H0 the model is fit.
Thus the test statistic is:
H = G∑
g=1
(Og −Eg)2
Ngpig(1 − pig) ∼ χ2G−2 (3.12)
Calibration Plots: This kind of plots represent, graphically, how close the estimates are from the
observed values. Thus, it plots the fitted outcome values against the observed ones. Within LR context,
this plotting may be not very pleasant as in a regression with continuous outcome values. Because of
this, this kind of representations within LR context, plots the mean of fitted values against the mean of
observed values, for each subgroup like in the Hosmer-Lemeshow Test.
3.1.7 Discriminative Power
Receiver Operating Characteristic (ROC): or ROC curve is a graphical feature that analyses the level
of discrimination of a binary classifier system (in this case, a LR). This curve measures the ability to
differentiate between Y=0 and Y=1. The fitted values Yˆ range between 0 and 1, but the real Y values are
{0,1}. There is the need to specify a cut-off value (c), in which one assumes Yˆ = 1 if Yˆ > c and Yˆ = 0 if
Yˆ < c .
For each c, there is a sensitivity value (P (Yˆ = 1∣Y = 1) estimated by #{yˆ=1,y=1}#{y=1} ) and a specificity value
(P (Yˆ = 0∣Y = 0) estimated by #{yˆ=0,y=0}#{y=0} ). The ROC curve is the representation of (x=1-specificity,
y=sensivity) for each value of c. The area under the ROC curve (AUC) is a discrimination measure, which
is defined as AUC = #{correct−discriminations}#{total−discriminations} .
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3.2 Generalized Additive Models
3.2.1 Introduction
Analyzing the expressions for the GLM (Equation 3.1), one realize that these impose a linear relation
between the independent variables and the dependent one. This lack of flexibility is a strong restriction
which, often, does not represent the true relationship between variables. This problem can be solved by
applying additive and generalized additive models. This type of models express the contribution of each
independent variable as a functional form defined through smoothing techniques. The first reference to
this kind of models was in 1947 (Leontief, 1947), but they were only brought to the spotlight by the end
of the eighties (Buja et al., 1989; Hastie and Tibshirani, 1990).
3.2.2 Additive Models
An additive model is defined through the following expression:
Y = α + k∑
j=1 fj(Xj) +  (3.13)
in which:
• The error term  is independent from the covariates X=(X1, . . . ,Xk), j = 1, . . . , k.
• E() = 0 and V ar() = σ2
• The partial functions fj , j = 1, . . . , k are :○ arbitrary functions, in most cases univariate functions○ smooth functions○ E[fj(Xj)] = 0⇒ E(Y ) = α
3.2.3 Estimation Algorithm
The estimation of each functional form (fj) regarding each independent variable (j = 1, . . . , k), is done by
the backfitting algorithm. First introduced in 1981 (Friedman and Stuetzle, 1981), its theoretical basis is
represented by Equation 3.14:
E[Y − α −∑
j≠k fj(Xj)∣Xk] = fk(Xk) (3.14)
Suppose there is the need to estimate the model E(Y ∣X1,X2) = f1(X1) + f2(X2). Let’s see how
it works from an informal point of view. From the initial estimate fˆ1(X1), one can estimate f2(X2)
through the smoothing of the residual Y − fˆ1(X1) on X2. Next, a better estimate of f1(X1) is obtained
smoothing Y − fˆ2(X2) on X1. This process will continue till fˆ1(X1) and fˆ2(X2) do not suffer major
changes in two consecutive iterations.
Formalizing the estimation of the partial functions fj = j = 1, . . . , k:
f1 =S1(y − . − f2 − ⋅ ⋅ ⋅ − fk)
f2 =S2(y − f1 − . − ⋅ ⋅ ⋅ − fk)⋮ =⋮
fk =Sk(y − f1 − f2 − ⋅ ⋅ ⋅ − .)
(3.15)
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being {fj = {fj(x1j), . . . , fj(xnj)}T with j = 1, . . . , k, Sj corresponds to the smoothing matrix on Xj
and the points (.) indicate the missing term in each row. This equation system can be written in the
following matrix system:
⎛⎜⎜⎜⎜⎝
I S1 . . . S1
S2 I . . . S2⋮ ⋱ ⋮
Sk . . . Sk I
⎞⎟⎟⎟⎟⎠
⎛⎜⎜⎜⎜⎝
f1
f2⋮
fk
⎞⎟⎟⎟⎟⎠ =
⎛⎜⎜⎜⎜⎝
S1y
S2y⋮
Sky
⎞⎟⎟⎟⎟⎠
This matrix system is solved using the backfitting algorithm. This way, one will obtain the estimates
of fj , for j = 1, . . . , k.
Considering a sample of n subjects, their responses are y=(y1, . . . , yn)T , and their observed covariate
values x are:
⎛⎜⎜⎜⎜⎝
x11 x12 . . . x1k
x21 x22 . . . x2k⋮ ⋱ ⋮
xn1 . . . xn(k−1) xnk
⎞⎟⎟⎟⎟⎠
The backfitting algorithm takes the following steps:
1. Initialization: Initialize αˆ = y¯ and fˆ(0)j = 0, or perform a linear regression Y on Xj , to obtain
fˆ
(0)
j = {fˆ (0)j (x1j), . . . , fˆ (0)j (xnj)}T
2. Cycle: for j = 1, . . . , k
• calculate the partial residuals:
rji = yi − y¯ −∑j−1k=1 fˆ (l+1)k (xik) −∑pk=j+1 fˆ (l)j (xik), i = 1, . . . , n
• calculate new fˆj estimates through the following expression: fˆ
(l+1)
j = Sjrj , being Sj the nxn
smoothing matrix regarding Xj , rj = (rj1, . . . , rjn)T the vector of partial residuals regarding
Xj , fˆ
(l+1)
j = {fˆ (l+1)j (x1j), . . . , fˆ (l+1)j (xnj)} and l the iteration count.
3. Repetition of step 2 till there are no more significant differences between fˆ
(l)
j and fˆ
(l+1)
j for every j.
The stoppage criterion can be defined as:
∑ni=1(fˆ (l+1)j (xij) − fˆ (l)j (xij))2∑ni=1(fˆ (l)j (xij))2 ≤ δ (3.16)
j = 1, . . . , p, for any δ small enough.
Through these models it is possible to estimate covariate functional forms that reflect more accurately
the true relationship between X and Y.
3.2.4 Generalized Additive Models
The generalized additive models are an extension of the generalized linear models, as the additive models
are an extension of the linear regression models. GAMs are more flexible than additive models because the
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additive predictor is linked to the response variable Y through a known link function g(⋅). This function g
is chosen based on the nature of Y and on the interest of the study, like in the GLMs context.
So, the GAMs are defined as:
g(µ) = α + k∑
j=1 fj(Xj)
µ = h(α + k∑
j=1 fj(Xj))
(3.17)
being µ = E(Y ∣X), with Y belonging to the Exponential Family, α and fj are unknown, j = 1, . . . , k.
3.2.4.1 Estimation Algorithm
In this context, the partial functions fj estimation is done through the local scoring algorithm (Hastie and
Tibshirani, 1986).
This algorithm is composed of two cycles, one (the backfitting algorithm) nested in another, as
described:
1. External Cycle Initialization: α(0) = h−1(n−1∑ni=1 yi) and fˆ(0)1 = ⋅ ⋅ ⋅ = fˆ(0)k = 0
2. External Cycle: For l = 0,1,2, . . . calculate the adjusted dependent variable:
z
(l)
i = ηˆ(l)i + (yi − µˆ(l)i ) (∂µˆl∂ηˆl )(l) (3.18)
and the weights:
wˆi = (∂µˆi
∂ηˆi
)2(l) (Vˆ (l)i )−1 (3.19)
, being ηˆ(l)i = αˆ(l) +∑pj=1 fˆ (l)j (xij), µˆ(l)i = h(ηˆ(l)i ), (∂µˆi∂ηˆi )(l) = ∂h∂η ∣η=ηˆ(l)i and Vˆ (l)i represents the
variance of Y calculated on µˆ(l)i , i = 1, . . . , n.
3. Internal Cycle (Backfitting for fˆ
(l+1)
estimation): Adjust an additive model to z = (z1, . . . , zn),
weighted by wˆ = (wˆ1, . . . , wˆn), in order to get fˆ(l+1)j , ηˆ(l+1)i and µˆ(l+1)i , with j = 1, . . . , k and
i = 1, . . . , n.
4. Repeat the steps 2 and 3 replacing fˆ
(l)
j , ηˆ
(l)
i , µˆ
(l)
i for fˆ
(l+1)
j , ηˆ
(l+1)
i , µˆ
(l+1)
i till the stoppage criterion
is met, for example:
∑ni=1(ηˆ(l+1)i − ηˆ(l)i )2∑ni=1(ηˆ(l)i )2 ≤ δ (3.20)
for any δ small enough.
It is noteworthy that the local scoring algorithm is not restricted to the backfitting in its internal cycle.
Any iterative process capable of solving equation 3.15 can be introduced.
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3.3 Some Basis in Epidemiology and Propensity Score Methodology
3.3.1 The Internal Validity of Observational Studies
In 1957, Campbell developed the internal validity concept which consists on 3 principles, that serve to
validate any inference relative to a cause-effect relationship (Campbell, 1957). Being C the cause and E
the effect, these are the principles:
• C must preceed E in time;
• C covaries with E;
• There is no other plausible explanation for this covariation.
Shadish et al identified many threats to internal validity (Shadish et al., 2002). But, the major threat
we face on observational studies is the selection threat. The selection threat is the risk of selecting
patients to treatment and control group, which are significantly different relative to their observable and
unobservable characteristics, in a way that bias the treatment effect estimate (selection bias) (Guo and
Fraser, 2009).
3.3.2 Confounding
In observational studies, the groups assigned to treatment or control are, naturally, imbalanced with
respect to many covariates. This is because these studies have to perform the analysis with pre-established
treatment groups where the treatment assignment is not randomized. In contrast, experimental studies
compare treatment groups where the distribution of certain/all variables is balanced. Here, the treatment
assignment is controlled and performed in order to assure the balance of covariates that potentially
influence the treatment effect estimate (potential confounders) between groups, through multiple
randomization methods (D ’agostino, 1998).
If one proceeds to estimate the treatment effect by directly comparing the treatment and the
control group, in an observational study, there is the risk to obtain a confounded/biased estimate (D
’agostino, 1998). This is due to covariates that have different distributions between treatment groups and,
simultaneously, have an association with the outcome (confounding variables). So, there is the need to
control/balance these type of variables, and therefore eliminate the selection bias/confoundness. Basically,
confounding is a distortion of an association between an exposure and an outcome brought about by
extraneous/confounding factors (Gordis, 2014).
Because of all this, the experimental studies are considered the ”gold standard”, and the observational
ones are often performed when there is lack of funding or when the experimental studies are not ethical or
simply infeasible (Meldrum, 2000).
3.3.3 Neyman-Rubin’s Counterfactual Framework
The intuitive idea of comparing two exactly equal populations relative to their characteristics, and assign
to one group the treatment and another group the control (the counterfactual), is to estimate an unbiased
treatment effect. Of course, this is often infeasible. As for each treated subject is very difficult to find
other subject in the control group with exactly the same characteristics (the counterfactual). This is a
missing data problem because it is unknown what would be the outcome of the treated subject if he was
assigned to control, and vice-versa (Austin, 2011a).
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The Neyman-Rubin’s counterfactual framework formalizes the idea that each individual has two
potential outcomes. The potential outcome if treated and the potential outcome if not treated, and only
one is observable (Guo and Fraser, 2009). This is because one subject cannot belong to the treatment
and to the control group, simultaneously. The equation 3.21 describes the basis of the Neyman-Rubin’s
Counterfactual Framework (NRCF).
Yi = ZiYi(1) − (1 −Zi)Yi(0) (3.21)
Where Zi is the dummy variable which represents the treatment received by subject i (1 or 0) , Yi(1)
the potential outcome if the subject is treated (Zi = 1) and Yi(0) the potential outcome if the subject
is not treated (Zi = 0). Yi is the ”observed” outcome for subject i, i.e., it is the outcome that results
from the treatment assignment to subject i. In this context, Zi functions as a switch variable because, if
Zi = 1⇒ Yi = Yi(1) and if Zi = 0⇒ Yi = Yi(0).
As only one outcome is observable, the other one is always missing. This is the missing data problem
stated before. In order to estimate the missing value, one could find a subject with the exact same x who
was assigned to the opposite treatment assignment condition and measure its outcome, but this is often
infeasible.
This missing outcome value can be estimated too by using a PS approach. Based on the properties of
PS, it is possible to select subjects which, assymptotically, have the same distribution of X. The outcomes
of these subjects are a great estimate of the unobserved potential outcome. This way, an unbiased treatment
effect estimate can be estimated.
3.3.3.1 Assumptions
As the context of this work will be within the NRCF, there are two assumptions that need to hold. To
prevent biased estimates due to unmeasured effects, Rosenbaum and Rubin proposed:
Ignorable Treatment Assignment Assumption (ITAA): This assumption, also known as the
unconfoundness assumption or the no unmeasured confounders assumption (Rubin and Rosenbaum, 1983),
holds when the treatment assignment (Z) is independent from the potential outcomes {Y (1), Y (0)}, if
the observable covariates X are held constant. ITAA is represented as:
{Y (1), Y (0)} ⊥ Z ∣X=x (3.22)
for all x where ⊥ means statistical independence.
In order to get an unconfounded estimate, the ITAA has to hold conditional on the observed covariates.
This assumption is violated if there are confounding variables that were not observed, and therefore will
provoke an hidden bias in the final estimate.
”This condition states that, for those having X = x, the assignment rule is determined by an
independent Bernoulli random variable having a probability of success Pr(Z = 1∣X = x)” (Emura et al.,
2008)
In Randomized controlled trials (RCT), this assumption holds naturally, because the randomization
balances the covariates X between treated and control groups. In this context, the treatment assignment is
independent from any covariate.
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Stable Unit Treatment Value Assumption (SUTVA) This assumption holds if the outcome variable
is independent from the mechanism used in treatment assignment, and from the treatments other units
receive.
3.3.4 Types of Treatment Effects
The treatment effect for each subject i is defined as Yi(1) − Yi(0). The Average Treatment Effect
(ATE) (denoted by τATE) is given by E[Y (1)] −E[Y (0)], and represents ”the average effect, at the
population level, of moving an entire population from untreated to treated.” (Austin, 2011a). If yi(1) and
yi(0) were observable for every subject, an estimate would be: τˆATE = 1n ∑ni=1 yi(1) − yi(0).
Other type of treatment effect is the Average Treatment Effect for the Treated (ATT) (denoted by
τATT ) which is given by E(Y (1)∣Z = 1)−E(Y (0)∣Z = 1) and represents the average effect of treatment
on those subjects who were treated. If yi(0) was observable for all treated subjects n1, an estimate would
be τˆATT = 1n1 ∑n1i=1 yi(1) − yi(0). ATT is particularly useful in policy contexts where the interest is not
whether the treatment is effective for all population, but if it is effective for those subjects who are targeted
to be treated. In a randomized study, these two measures coincide because the treated population will not
differ from the overall population.
These treatment effects are marginal effects, i,e. they measure the average treatment effect on the
population. These are different from the Conditional effects that arise when performing any kind of
regression, and, usually, are represented by the β coefficients.
”A marginal effect is the average effect of treatment on the population. A conditional effect is the average
effect of treatment on the individual” (Austin, 2011a).
3.4 The Propensity Score
In 1983, Rosenbaum and Rubin proposed an alternative and innovative method to estimate the treatment
effect in observational studies, removing the effects of confounding: the propensity score analysis.
The propensity score is the conditional probability of assignment to a particular treatment given a
vector of observed covariates. Assuming e(X) the propensity score, Z the treatment assignment variable
and X the covariates:
e(X) = Pr(Z = 1∣X). (3.23)
The unique properties of the propensity score (PS) allow the treatment effect estimation, in multiple
ways (described further). PS is a balancing score, which means that the distribution of X is similar in both
treated and control groups, conditionally on e(X). This large sample property is defined as:
X ⊥ Z ∣e(X). (3.24)
It means that if two populations (treated and non-treated) have the same value of e(X), the outcome
mean difference between them is an unbiased estimate of the treatment effect, if X contains all the
confounding variables (i.e. if ITAA holds). Populations with the same e(X) are comparable because they
have the same distribution regarding potential confounding variables. This is why PS analysis has the
ability to, partly, mimic a randomized study.
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This balancing property allows to replace X by e(X) in the analysis, which is particularly useful when
X is of high dimension. Because of this, e(X) can be used in matching, stratification and LR replacing X.
”The Propensity score e(xi) is a balancing measure (so called the coarsest score) that summarizes
the information of vector xi in which each x is the finest score.” (Guo and Fraser, 2009).
Propensity Score Model The first step in every propensity score analysis, is to estimate the propensity
score for every subject eˆ(xi). This is, usually, done through a logistic regression, where the treatment
assignment variable (Z) is the dependent variable and X the independent variables. The fitted values of
this LR are the estimated propensity scores. The selection process by which the independent variables are
selected to be part of the model is discussed further.
e(X) = Pr(Z = 1∣X) = exp(β0 + β1X1 + ⋅ ⋅ ⋅ + βkXk)
1 + exp(β0 + β1X1 + ⋅ ⋅ ⋅ + βkXk) (3.25)
3.5 Propensity Score Matching
3.5.1 Traditional Matching
The objective of this section is to introduce the concept of matching. The first matchings consisted on
pairing each treated subject with other subjects who were not treated, with similar specified observed
covariates x. This covariates are the ones that are unbalanced between groups and are potential confounding
variables. Consider yj1 and yj0 the observed outcomes of the jth pair (j = 1, . . . , n), and Dj = Yj1 − Yj0.
The treatment effect (τ ) estimate can be obtained like this:
τˆ = D¯ = 1
n
∑
j
(yj1 − yj0) = y¯1 − y¯0. (3.26)
If the outcome is continuous, τˆ is the estimated mean outcome difference between groups. If the
outcome is dichotomous, τˆ is the estimated difference between the proportion of subjects experiencing
the outcome event in each group.
As the estimate derives from a paired experiment, the variance of the estimate has to be calculated
accordingly . For a continuous outcome, can be used a paired t-test, and for a dichotomous one can be
used the McNemar’s Test (Imbens, 2004).
By pairing subjects whose values on the confounding variables are similar, a greater fraction of the
difference in the outcome (Dj), is due to the treatment assignment, and a lesser fraction is due to the
confounder (Rubin, 1973) .
If there are many covariates to match on, it is possible few pairs being matched, which jeopardizes the
significance of the estimate. For example, suppose there are k dichotomous covariates to match on, it
means that exist 2k possible values of x. This problem is called the dimensionality of matching.
3.5.2 Matching on the Propensity Score
Basically the same as matching on X. But, instead of pairing based on the covariates X, the pairing is
done through eˆ(x). Treated subjects are paired with non-treated subjects, if both have similar values
of eˆ(x). This is done because subjects with the same eˆ(x), have, asymptotically, the same multivariate
distribution of X and, therefore, are comparable (Remind the large sample property on Equation 3.24).
This leads back to the Neyman-Rubin Counterfactual Framework because matching is all about finding
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counterfactuals for the treated subjects, so that one can compare the outcome of a treated subject Yi(1) to
the outcome of its counterfactual Yˆi(0), and therefore obtain a treatment effect estimate for the treated
τi,ATT = Yi(1) − Yˆi(0)∣Zi = 1. That is why, this work is within the NRFC.
So, if the matching is done based on eˆ(x), the two matched samples will share the same distribution
of X. This matching approach address the dimensionality of matching problem.
In practice, the matching is not done on eˆ(x), but on its tranformation (i.e., qˆ(x) = log[(1−eˆ(x))/eˆ(x)]
). This way, the qˆ(x) values are not compressed between 0 and 1 like eˆ(x) and are more likely to be
normal distributed which is an advantage in genetic matching (described further) (Rosenbaum and Rubin,
1985).
There are several choices to be made when applying matching:
• Greedy or Optimal In greedy matching, at first, a treated subject is chosen at random. Then,
this treated subject is matched with an untreated subject whose eˆ(x)(PS) is the closest to the
PS of the treated subject. This process is repeated until all the treated subjects are matched (if
there is a suitable match for every treated subject). This is called ”greedy” because it does not
minimize the total within-pair PS difference , contrary to optimal matching. It was proved that both
methods have the same performance in the production of balanced matched samples (Austin, 2011a).
The most common algorithm to match subjects on the PS is a greedy one called Nearest Neighbour
Matching with a Specified Caliper Distance(NNM-CD). This algorithm is very simple and efficient.
Basically, it states that each treated subject is matched with the untreated subject whose PS is the
closest, but this difference cannot exceed a pre-specified threshold. This limit is called caliper
distance. If a given treated subject have no untreated subjects whose PS lays within the caliper
distance, this subject remains unmatched and is excluded from the analysis. Austin suggested to
use a caliper distance that is 0.2 of the pooled (treatment and control groups) standard deviation of
the PS estimates. (Austin, 2011b).
• Replacement or No Replacement If the option is matching without replacement, every untreated
subject that is matched with a treated subject, is no longer available for matching thereafter. On
the other hand, if matching with replacement is chosen, an untreated subject can be matched with
multiple treated subjects. Matching with replacement produces the most balanced samples and
the lowest conditional bias. Matching with replacement produces matches of higher quality than
matching without replacement by increasing the set of possible matches (Abadie and Imbens, 2006).
Common Support Region Problem In order to match a substantial number of pairs, it is needed that
the two groups (treated and non-treated) have similar estimated propensity scores distributions. If it is not
the case, at least, the two distributions have to share a common support region to let a sufficient number of
pairs to be formed. This is called the overlap assumption.
For example, in the figure 3.1, the overlap assumption is not violated because there still is a significant
common support region. If this assumption is violated, matching estimators are not appropriate.
3.5.3 Variable Selection
The covariates chosen to be introduced in the PS model (Equation 3.25), have to be selected in order
to find the PS estimates that most balance the matched treatment groups, regarding the covariates that
23
Figure 3.1: Example: Estimated propensity scores qˆ(x) distributions in treated and non-treated groups. Represented by a
box-plot.
influence the outcome. The variables introduced in the model are the ones that will be controlled/balanced
between the matched treatment groups, as stated by the balancing property X ⊥ Z∣e(X). Thus, it would
be obvious to include only the variables that are prognostically important, but the identification of these
variables is not straightforward. Because of this, there are four possible variable subsets that are commonly
tested within the PS model:
• True Confounders (variables associated with both treatment assignment and the outcome);
• Potential Confounders (variables associated with the outcome );
• Variables associated with the treatment assignment;
• All observed variables.
The introduction of potential confounders or true confounders in the model proved to generate more
precise treatment effect estimates than subsets 3 and 4. This makes sense because, in this case, the
procedure is focused in balancing only these variables. Although, if there are unidentified confounding
variables, the estimate will be biased. Including all observed covariates in the model, i.e. balancing
all observed variables between the matched treatment groups, is reassuring because the identification
of confounders can be tricky. Other option is to include only the variables that are associated with the
treatment assignment, assuming that all the other variables will be balanced after matching because they
do not influence the treatment assignment. In simulation studies, all subsets produce equally biased
estimates (Austin et al., 2007).
Figure 3.2: Search for the best Propensity Score model. Figure taken from Diamond and Sekhon (2012).
Treatment and control subjects are matched on PS, in order to obtain two comparable populations
with the same X distribution of interest, and therefore to estimate the treatment effect. If the matched
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samples are balanced regarding this X variables included in the model, it means the propensity score
model serves our best interest and the matching was successful. If the matched groups are not balanced,
there is the need to reformulate the PS model (e.g. by including/excluding a square term of a covariate
or an interaction term) (Figure 3.2). Insights on variable balance within the matched samples will be
presented further.
In this context, discriminative and predictive power measures are not sufficient to access the PS model
correctness (Stu¨rmer et al., 2006). This because, our main objective is to balance the treatment groups
regarding the covariates within the PS model and not to predict the treatment assignment probability.
”Since the propensity score (e(X)) is a balancing score (Z ⊥ X∣e(X)), the estimate of the propensity
score is consistent only if matching on this propensity score asymptomatically balances the observed
covariates.” (Diamond and Sekhon, 2012)
3.5.4 Balancing Diagnostics
To assure that matching was successful, one needs to check if both groups have the same distribution
regarding the variables within the PS model. If this happens to be, the PS estimates are consistent because
the PS model is well specified, if not, the PS model needs to be changed in order to improve balance.
The best way to access the covariates balance between groups. One of them is the Standardized Mean
Difference (SMD) . This measure is defined as
d = (x¯treatment − x¯control)√
s2treatment+s2control
2
for continuous variables, and
d = (pˆtreatment − pˆcontrol)√ (pˆtreatment)(1−pˆtreatment)+pˆcontrol(1−pˆcontrol)
2
for dichotomous variables, where x¯ denote the group mean for a continuous variable, s2 the group sample
variance and pˆ the group proportion for a dichotomous variable. If d is less than 0.1, the difference
between groups regarding that specific variable is considered negligible (i.e. the null hypothesis H0 is not
rejected for H0 ∶ µT = µC) (Normand et al., 2001).
Significance tests like the T-test, Mann-Whitney or Kolmogorov Smirnov should not be used in
these circumstances because the significance levels can be confounded with sample size (Flury and
Riedwyl, 1986; Austin, 2008). This means that when the sample size is very large, the differences are
very likely to be statistically significant. Other way to analyse the balance is to apply graphical methods
like side-by-side box plots, quantile-quantile plots or cumulative distribution functions.
3.5.5 Genetic Matching
This section is about the Genetic Matching algorithm published by Diamond and Sekhon (2012), and
implemented by the R package Matching.
The genetic matching is a process that iteratively modifies the matching metric to achieve a maximum
covariate balance between groups.
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In the previous version of matching, subjects were matched simply on their PS. In genetic matching,
subjects are matched on the Generalized Mahalabonis Distance (GMD) between them. But, first of all, we
must review the concept of Mahalanobis Distance (MD).
Mahalanobis Distance MD is a multivariate distance measure between two subjects. MD is unitless
and scale-invariant, and takes into account the correlations between variables. For example, MD between
the subject i and j, whereX is the covariate matrix (nxk) and S is the sample covariate matrix (nxn) of
X , is represented this way:
MD(Xi,Xj) = √(Xi −Xj)TS−1(Xi −Xj).
This measure can be used to match the subjects, but it has a low performance when covariates have
non-ellipsoidal distributions. This is why Rosenbaum and Rubin (1985) proposed to include the PS
estimates among the other covariates in X. Thus, all the covariates are represented through the PS estimates.
Generalized Mahalanobis Distance(GMD) GMD is very similar to MD. The only difference is that
GMD assigns weights (W ) to all matching variables. These weights are assigned by the algorithm and
reflect the importance of each variable to achieve the best overall balance. Considering W the weight
matrix (kxk), and considering thatW is restricted to 0 except for the main diagonal, the GMD between
two subjects i and j is:
GMD(Xi,Xj ,W ) = √(Xi −Xj)T (S−1/2)TWS−1/2(Xi −Xj).
If the maximum balance is achieved by matching on the PS, the W matrix will have all its values restricted
to 0 except the one regarding the PS covariate. If the maximum balance is achieved by matching on the
MD, the main diagonal will have values greater than 0, except for the PS covariate value.
Loss Function There is the need to choose which statistic will be used to access the balance. The
most popular choices are the standardized mean difference and the KS statistic. Examples of loss
functions are the maximum value of the KS statistic or the maximum standardized mean difference across
all variables. If the loss function is lower, the sample is better balanced on X. Otherwise, if it is higher,
the balance is worse. The all point of genetic matching is to search, iteratively, for a specificW matrix
that minimizes the loss function.
Iterative Algorithm The genetic matching search for the idealW matrix. First, it generates a batch
ofW matrixes. Next, perform as many matchings as the number ofW matrixes. Then, compute the loss
function for every matched sample. The matched sample with the lowest loss function value is selected,
and its W matrix will be used to generate a new similar batch of W matrixes. This algorithm moves toward
the minimum loss function value possible. The algorithm stops running when the maximum number of
iterations is reached. This procedure is depicted in figure 3.3.
This type of matching cannot be used to access the PS model correctness, because the PS estimated
values are not used directly on matching. Therefore, the balancing score property (Z ⊥X ∣e(X)) is not
available for checking.
To conclude, GM tries to search for the GMD metric which provides the most balanced matched
sample. Basically, this algorithm matches the subjects, evaluate the balance and continues to learn
iteratively. In this context, one still needs to opt between matching with or without replacement, and
between greedy and optimal.
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Figure 3.3: Representation of Genetic Matching. Figure Taken from Diamond and Sekhon (2012)
3.5.6 Estimation of the Average Treatment Effect for the Treated
To perform matching one have to select subjects from the non-treated group that are the counterfactuals,
i.e. comparable regarding some covariates, to every subject in the treated group. These counterfactuals
outcomes are an estimate of the potential outcome if the treated have not been treated (Yˆi(0)). This way,
matching is trying to estimate the Average Treatment Effect for the Treated (ATT), and not for all the
population (Deb et al., 2015). ATT is calculated as the mean difference between treated and control
matched subjects, for each ith treated subject :
τˆATT = 1
n
∑
i
Yi(1) − Yˆi(0) (3.27)
Abadie and Imbens (2002) developed a variance estimator for τˆATT . This estimator, under
homoscedasticity conditions: 1) τi = Yi(1) − Yi(0) is constant and 2) the conditional variance of Yi(Z)
given Xi does not vary with the treatment Z, is given below.
This variance estimator needs to account if the matching is done with replacement. Because of that,
the expression that calculates the variance is complex. Let JM(l) denote the set of indices relative to
the subjects that are matched to unit l, and #JM(l) the number of indices within the set. Let KM(i) be
the total number of times i is used as a match for all observations l of the opposite treatment condition,
each time weighted by the total number of matches for observation l: KM(i) = ∑Nl=1 1{iJM(l)} 1#JM (l) ,
being 1{●} the indicator function. And, K ′M(i) = ∑Nl=1 1{iJM(l)}( 1#JM (l))2.
The estimator variance is:
V ar(τˆATT ) = 1
N21
N∑
i=1[Zi(Yi1 − Yi0 − τATT )2 + (1 −Zi)(K2M(i) −K ′M(i))
1
2N1
∑
i∶Zi=0{ 1#JM(i) ∑lJM (i)(Yl − Yi − τˆATT )2}]
(3.28)
where N1 is the number of subjects treated, and N the total number of subjects. This variance can be
used to perform a significance test or to calculate a confidence interval, because τˆATT−τATT√
V ar(τˆATT ) ∼ N(0,1)
allowing a z test. Being the CI given by:
{τˆATT ± z1−α/2 ×√V ar(τˆATT )}. (3.29)
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3.6 Stratification
Stratification is a Matching generalization. Instead of pairing 1 on 1 subjects, stratification consists on
creating groups (strata) which the subjects within each stratum have, roughly, the same PS estimate. To
create these strata, PS estimates quantiles (typically quintiles) are often used as stratum delimiters. If the
stratification is performed on 5 strata, quintiles are used, if performed on 10 strata, deciles are used. This
stratification method is based on equal-frequency strata, but other stratification methods are valid as well
(Huppler Hullsiek and Louis, 2002).
Stratification takes advantage of the PS balancing property, as matching does. Here, any subject
(treated or non-treated) within the same stratum has, roughly, the same X distribution. This makes the two
treatment groups comparable within each stratum (Rosenbaum and Rubin, 1984).
The utility of Stratification has been proved a long time ago. Stratifying (using quintiles) on one
confounding variable (not on PS estimates) was proved to reduce the confounding by 90% (Cochran,
1968). In 1984, Rosenbaum and Rubin extended this result to the PS stratification, which reduces the
effects of confounding due to measured confounders by, approximately, 90% as well (Rosenbaum and
Rubin, 1984). As the number of strata increases, the bias reduction is improved, but the ATE estimate
variance increases (Huppler Hullsiek and Louis, 2002).
3.6.1 Estimation of the Average Treatment Effect
Here the ATE (Average Treatment Effect) is estimated this way:
τˆATE = 1
K
K∑
j=1 τˆATEj = 1K
K∑
j=1 y¯1j − y¯0j , (3.30)
being K the number of strata, y¯1j the mean outcome of the treated subjects in stratum j, y¯0j the mean
outcome of the non-treated subjects in stratum j, and τˆATEj the stratum specific estimate.
The τˆATE estimator variance is estimated this way:
V ar(τˆATE) = 1
K2
K∑
j=1V ar(τˆATEj) = 1K2
K∑
j=1 σˆ2j , (3.31)
being the stratum-specific variance estimate σˆ2j :
σˆ2j = 1n1j s21j + 1n0j s20j (3.32)
with
s21j = 1n1j
nj∑
i=1(ZiYi − y¯1j)2 s20j = 1n0j
nj∑
i=1{(1 −Zi)Yi − y¯0j)}2
y¯1j = 1
n1j
nj∑
i=1ZiYi y¯0j = 1n0j
nj∑
i=1 (1 −Zi)Yi2
(3.33)
nj the number of subjects in stratum j, n1j the number of treated subjects in stratum j, n0j the number
of non-treated subjects in stratum j. Zi and Yi, the treatment assignment and the outcome for each subject i.
As τˆATE−τATE√
V ar(τˆATE) ∼ N(0,1), so a z test is possible. Being the CI given by:
{τˆATE ± z1−α/2 ×√V ar(τˆATE)}. (3.34)
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3.7 Inverse Probability of Treatment Weighting
Inverse Probability of Treatment Weighting (IPTW) using PS is a weighting technique that creates a
synthetic sample in which the distribution of measured confounders is independent of the treatment
assignment (mimicking this way a randomized clinical trial). IPTW consist on weighting more the
subjects that represent populations that are less represented within a specific treatment group. When the
word ”population” appears in this context, it means: subjects with roughly the same PS and therefore
with, asymptotically, the same X.
It is natural that subjects with higher PS estimates are more likely to receive treatment, and therefore,
the most represented populations in the treated group are the ones that correspond to higher PS and
vice-versa. To achieve synthetic samples that represent the all population, the strategy is to weight more
the subjects with lower PS estimates in the treated group and the subjects with higher PS estimates in the
non-treated group. These weights are the inverse of the probability of receiving the treatment actually
received. So, for each subject the weight is:
wi = Zi
ei
+ 1 −Zi
1 − ei , (3.35)
being Zi the treatment assignment and ei the PS for subject i (Austin, 2011a). The sum of weights is
roughly equal in both treatment groups, although the number of subjects in each group may be very
different. For the treated subjects (i = 1, . . . , n1), ∑n1i=1wi = ∑n1i=1 1ei ≈ n0 + n1 = n and for the non-treated
subjects (j = 1, . . . , n0),∑n0j=1wj = ∑n0j=1 11−ej ≈ n0+n1 = n. This means that the new weighted (synthetic)
samples have the same dimension (the total number of treated and non-treated n). These new samples
represent the all range of populations (i.e. the all range of the PS estimates), and therefore are great to
estimate the ATE.
3.7.1 Estimation of the Average Treatment Effect
The ATE is estimated by a weighted mean, using the weights referred before:
τˆATE = 1
n
n1∑
i=1Yiwi − 1n
n0∑
j=1Yjwj
= 1
n
n1∑
i=1Yi
1
eˆi
− 1
n
n0∑
j=1Yj
1
1 − eˆj
= 1
n
n∑
i=1Yi
Zi
eˆi
− 1
n
n∑
i=1Yi
1 −Zi
1 − eˆi .
(3.36)
The variance of τˆATE estimator is estimated this way:
V ar(τˆATE) = 1
n2
n∑
i=1 Iˆ2i , (3.37)
being
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Iˆ2i = ZiYieˆi − (1 −Zi)Yi1 − êi − τ̂ATE − (Zi − eˆi)ĤTβ,1Ê−1ββWi
ĤTβ,1 = 1n n∑i=1{ZiYi(1 − eˆi)eˆi + (1 −Zi)Yieˆi1 − eˆi }Wi
Ê−1ββ = 1n n∑i=1 eˆi(1 − eˆi)WiWTi
eˆi = 1/{1 + exp(−WTi β)}
W = XT (if PS estimated by LR)
(3.38)
A z test is possible to compute because τˆATE−τATEV ar(τˆATE) ∼ N(0,1).
3.8 GLM and PS mixed approach: Covariate Adjustment
As seen before, the PS has the ability to replace the vector of covariates X in multiple analysis. Thus,
using the PS as a covariate in a GLM is also an option.
The model proposed here consists on the outcome (Y ) as the dependent variable, and as independent
variables:
• the treatment assignment (Z);
• Prognostically Important variables (X1,X2, . . . ,Xp);
• the PS estimated based on all the other variables (e(Xp+1,Xp+2, . . . ,Xk)).
The prognostically important variables are described by Hirano and Imbens as the variables that are
worth to be included in the model individually, i.e., the variables that are associated with the outcome
(Hirano and Imbens, 2001). The PS estimated based on all the other observed variables are like a
complement to the model. The term e(Xp+1,Xp+2, . . . ,Xk) is seen as a summary of all ”non-important”
variables that are not relevant enough to be individually on the model.
As in the context of this work, the outcome variable is dichotomous, so, a logit link will be used. The
β coefficients estimation is the same as in 3.1. The referred model is given by:
log( pi
1 − pi ) = β0 + β1Z + β2X1 + β3X2 + ⋅ ⋅ ⋅ + βp+1Xp + βp+2e(Xp+1,Xp+2, . . . ,Xk). (3.39)
This approach is an attempt to build a more parsimonious model. This is, particularly, useful when
there are large number of variables to control.
3.9 Comparison of all Propensity Score Methods
Table 3.4 summarizes advantages and disadvantages of each PS method described before.
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Table 3.4: Advantages and Disadvantages of all PS methods and their respective Treatment Effect Estimated. Table retrieved,
partly, from Deb et al. (2015)
Methods Advantages Disadvantages Treatment
Effect
Estimated
Matching
● Superior at reducing
bias compared with
stratification and covariate
adjustment
● Unmatched treated participants,
and possibly unmatched control
participants, are excluded from
the analysis, decreasing precision
of the treatment effect estimate
and external validity
ATT
● Requires more control
participants than treated
participants
Stratification ● Uses all Data ● Reduces bias less than
matching and IPTW
ATE
IPTW
● Superior at reducing
bias compared with
stratification and covariate
adjustment
● May be more sensitive
to mis-specification of the
propensity-score model and
extreme propensity-score values
ATE
● Uses all Data
Cov. Adjust.
● Uses all Data ● No clear distinction between
the design phase and the analysis
phase
OR
● Very Biased estimates
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3.10 Comparison between Propensity Score and Regression Methods
Historically regression methods have been more used than Propensity Scores (PS) when analysing
observational data (Austin et al., 2007). This happens because regression methods allow to identify
indivually the factors responsible for the outcome, something that PS analysis is unable. However,
Propensity Scores are increasingly being used as a strategy to control confoundness (Arbogast and
VanderWeele, 2013), and the reasons why are explained right away.
In the cardiology context, tendentiously there are many variables to control, which can be problematic
for regression methods to succeed. Previous research suggested a minimum of 10 events for each covariate
included in the regression model (Peduzzi et al., 1996). In PS analysis, even if the event of interest is rare
and treatment/non-treatment is common, one can control for all baseline variables successfully, contrary
to what happens in regression methods (Braitman and Rosenbaum, 2002). This because the probability of
treatment assignment (i.e. the propensity score) is estimated in good conditions according to Peduzzi et al.
(1996) (1 covariate for each 10 events), even if the events are rare. This is the main reason why Propensity
Scores were used in this work, because the events are rare (27) and the propensity scores can be estimated
in good conditions by logistic regression or generalized addictive models.
Additionally, PS analysis has advantages like the separation between design phase (when Propensity
Score estimates are obtained) and analysis phase. In regression methods, the treatment effect estimate
is always observable while building the model, thus this can be a temptation to continually modify the
model until the desired association is achieved. In PS analysis, only after checking the balance of the
baseline covariates (design phase) the analysis is performed.
Another great advantage of PS analysis is that one can, explicitly, compares two treatment groups
regarding the observed baseline covariates. If the two populations are not comparable regarding the
prognostically important variables (i.e. if there is no overlap), the PS analysis is not correct. This is an
intuitive thought too, if two populations are not comparable any treatment effect estimation is possible.
Using regression methods, it is difficult to access this overlap. So, if one tries to apply a regression-based
approach to treatment groups with no overlap, an interpolation is being made between two different
populations (Austin, 2011a).
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Chapter 4
Results
4.1 Logistic Regression
4.1.1 Univariate Analysis
First of all, an univariate logistic regression (LR) is performed to find the variables that are useful to
explain the outcome variable. All variables that have a p-value lower than 0.25 in its univariate logistic
regression, are selected to be part of the preliminary model. The descriptive analysis and the corresponding
univariate p-values for every variable observed are shown in Table 4.1.
Table 4.1: Contingency tables for every categorical variable in the dataset regarding each study endpoint group. Average and
Standard Deviation(SD) for continuous variables with normal distribution and Minimum(min.)/Median/Maximum(max.) for
non-normal continuous variables, regarding each study endpoint group. p-value obtained from the univariate logistic regression
(LR).
Variable Variable Values
Non-occurrence
of Stroke or
TIA (n=16683)
Occurrence of
Stroke or TIA
(n=27)
Total LR p-value
Demographic
Age QC Average (SD) 65.79(11.59) 67.07 (10.93) 16710 0.565
Male Gender
0 Count (%) 5565 (99.8%) 11 (0.20%) 5576
0.418
1 Count (%) 11118 (99.9%) 16 (0.14%) 11134
BMI Average (SD) 27.36 (4.04) 27.15 (3.44) 0.786
Cardiovascular Risk Factors
Diabetes Mellitus
0 Count (%) 11988 (99.8%) 19 (0.16%) 12007
0.8641 Count (%) 4695 (99.8%) 8 (0.17%) 4703
Hypertension
0 Count (%) 4493 (99.9%) 6 (0.1%) 4499
0.582
1 Count (%) 12190 (99.8%) 21 (0.17%) 12211
Smoking
0 Count (%) 10092 (99.8%) 17 (0.2%) 10109
0.793
1 Count (%) 6591 (99.8%) 10 (0.15%) 6601
Dyslipedemia
0 Count (%) 6665 (99.9%) 6 (0.09%) 6671
0.068
1 Count (%) 10018 (99.8%) 21 (0.21%) 10039
Prior Clinical History
MI
0 Count (%) 13118 (99.8%) 23 (0.18%) 13141
0.410
1 Count (%) 3565 (99.9%) 4 (0.11%) 3569
PCI
0 Count (%) 12758 (99.8%) 22 (0.17%) 12780
0.541
1 Count (%) 3925 (99.9%) 5 (0.13%) 3930
CABG
0 Count (%) 15149 (99.8%) 24 (0.16%) 15173
0.731
1 Count (%) 1534 (99.8%) 3 (0.20%) 1537
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Stroke/TIA
0 Count (%) 15399 (99.8%) 27 (0.18%) 15426
0.985
1 Count (%) 1284 (100.0%) 0 (0.00%) 1284
PAD
0 Count (%) 14765 (99.8%) 25 (0.17%) 14790
0.536
1 Count (%) 1111 (99.9%) 1 (0.09%) 1112
Non CABG Surgery
0 Count (%) 16259 (99.8%) 26 (0.16%) 16285
0.703
1 Count (%) 424 (99.8%) 1 (0.24%) 425
Renal Transplant
0 Count (%) 16613 (99.8%) 27 (0.2%) 16640
0.988
1 Count (%) 70 (100.0%) 0 (0.00%) 70
Clinical Setting and Procedural Characteristics
Interventional procedure
0 Count (%) 9722 (99.8%) 15 (0.15%) 9737
0.775
1 Count (%) 6961 (99.8%) 12 (0.17%) 6973
Acute Coronary Syndrome
0 Count (%) 10485 (99.8%) 21 (0.20%) 10506
0.117
1 Count (%) 6198 (99.9%) 6 (0.10%) 6204
Aortic Valvulopathy
0 Count (%) 15465 (99.8%) 25 (0.16%) 15490
0.983
1 Count (%) 1218 (99.8%) 2 (0.16%) 1220
Systolic Blood Pressure QC Average (SD) 139.14 (28.16) 146.08 (29.26) 16489 0.209
Diastolic Blood Pressure QC Average (SD) 72.27 (13.05) 76.42 (15.16) 15902 0.104
Coronary artery disease extension QD min./median/max. 0/1/3 0/1/3 16710 0.932
Number of Treated Segments QD min./median/max. 0/1/3 0/1/3 15902 0.748
Fluoroscopy Time QC min./median/max. 0.24/7/105 1.45/6.40/40.30 16039 0.477
Contrast Volume QC min./median/max. 10/100/1100 40/91/300 15269 0.584
Number of Catheters Used QD min./median/max. 1/3/15 1/3/6 15902 0.972
Transradial Approach 0
Count (%) 12459 (99.8%) 20 (0.16%) 12479
1 Count (%) 4224 (99.8%) 7 (0.17%) 4231 0.942
QC: Quantitative Continuous; QD: Quantitative Discrete
Table 4.2: Odds ratio estimates and the corresponding 95% confidence intervals (CI) from the Univariate logistic regression,
regarding the variables under study with a p-value less than 0.25 and the exposure (Transradial Approach).
Variable OR
95 % CI
Lower Higher
Dyslipidemia 2.33 0.93 5.77
Acute Coronary Syndrome 0.48 0.19 1.20
Systolic Blood Pressure 1.01 0.995 1.022
Diastolic Blood Pressure 1.02 0.995 1.053
Transradial Approach (Exposure) 1.03 0.44 2.44
The variables included in the preliminary model are: Dyslipidemia, the Acute Coronary Syndrome
history, the Systolic and Diastolic Blood Pressure levels. The exposure variable Transradial Approach
was included too. Although the variable does not have statistical significance, it is included in the model
because it is our objective to access its contribution to the outcome. The OR and the respective 95%
confidence interval, for every variable in the preliminary model are displayed in Table 4.2.
The univariate logistic regression only produces reliable results if there is a linear relation between the
values of the variable and the outcome probability logit (log p1−p ). If this assumption does not hold, and
one only relies on the logistic regression to access the importance of some variable, there is the risk to
undervalue its contribution (Hastie and Tibshirani, 1986). And, as bad as undervalue its contribution,
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Figure 4.1: Univariate GAM functional forms regarding Age, BMI, Systolic BP, Diastolic BP, FLuoroscopy Time and Contrast
Volume as covariates and Stroke/TIA as the dependent one. The functional form is represented by the filled lines and the
confidence intervals are represented by the dashed lines.
is to build a model which do not represent the true relationship between the variable and the outcome
(Hastie and Tibshirani, 1986). For this reason, an univariate GAM was performed to access the linearity
assumption of each continuous variable. All of these variables proved to be linear relative to the logit of
the outcome probability and, so, the results from the univariate logistic regression results are reliable
(Figure 4.1). The splines used here and throughout this work are thin-plate regression splines.
If some continuous variable is not statistically significant in a LR context, it does not mean that it
cannot provide relevant information. Because of this, categorizing variables can be useful to explain the
outcome response. There are some variables, that otherwise would never be statistically significant if they
remained continuous (Mazumdar and Glassman, 2000).
In an attempt to categorize some continuous variables and check for their significance, a minimum
p-value approach was performed. The minimum p-values and their respective cutpoints are shown in
Table 4.3, and the whole process is depicted in Figure 4.2. The variables Age, Systolic Blood Pressure,
Diastolic Blood Pressure and Fluoroscopy Time have p-values (from the χ2 tests) lower than 0.25 at their
respective cutpoints. For this reason, the categorized versions of these variables (Age65, Systolic Blood
Pressure147, Diastolic Blood Pressure72 and Fluoroscopy Time10) will be included in the preliminary
model.
Of course, it makes no sense including Diastolic Blood Pressure and its categorized analog in the
same model. So, it was decided to include the categorical variable Diastolic Blood Pressure72 because
throughout the model selection process, the models with this variable had more discriminative power
(measured by AUC), and roughly the same predictive power (measured by calibration plots) than the
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Figure 4.2: Minimum p-value approach to the quantitative continuous variables. Dashed lines represent the minimum p-value
(horizontal), and the corresponding cutpoint (vertical).
model with its continuous counterpart. Regarding the Systolic Blood Pressure, the continuous analog was
the chosen one for the same reason.
Table 4.3: Minimum p-value approach regarding Quantitative Continuous Variables
Variable Cutpoint p-value (χ2 test)
Age 65 0.129
BMI 32 0.309
Systolic Blood Pressure 147 0.102
Diastolic Blood Pressure 72 0.046
Fluoroscopy Time 10 0.160
Contrast Volume 92 0.378
4.1.2 Multivariable Analysis
The preliminary model to describe the ocurrence of peri-procedural Stroke/TIA contains the following
variables: Transradial Approach, Dyslipidemia, Acute Coronary Syndrome, Systolic Blood Pressure,
Diastolic Blood Pressure72, Age65 and Fluoroscopy Time10. The final model was chosen, by removing
the variables without statistical significance (p-value<0.10 for the Wald Test). All removing steps were
based on decreasing AIC values (Backwards Stepwise). There were no identified interactions . The final
model is depicted in Table 4.4 and is composed of the following variables: Dyslipidemia, Age65, Diastolic
Blood Pressure72 and Fluoroscopy Time10 as the prognostically significant. The Hosmer-Lemeshow Test
proved the model to be significant and well fitted because the Hosmer-Lemeshow Test p-value is 0.997
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(Table 4.4). The calibration plot shows an acceptable predictive power (Figure 4.3a and Table 4.5) and the
ROC curve with an AUC=0.731 shows a good discriminative power (Figure 4.3b and Table 4.4) .
Table 4.4: Final Model. Estimated coefficients, Odds Ratios, the corresponding 95% Confidence Intervals, the p-values from the
Wald Tests, the Hosmer-Lemeshow p-value and the AUC value.
Variable βˆ OˆR
95% CI
p-value Hosmer AUC
Lower Higher
Transradial Approach 0.114 1.121 0.467 2.689 0.799
0.997 0.731
Dyslipidemia 1.290 3.631 1.245 10.593 0.018
Age65 0.810 2.247 0.959 5.265 0.062
Diastolic Blood Pressure72 0.976 2.653 1.133 6.208 0.025
Fluoroscopy Time10 -0.885 0.413 0.154 1.102 0.077
(a) Calibration plot (b) ROC curve
Figure 4.3: Calibration Plot and ROC curve regarding the model in Table 4.4.
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Table 4.5: Hosmer-Lemeshow predicted risk bins. For each bin: Mean predicted and mean observed events, total predicted and
total observed events. (model from Table 4.4).
Bins Total Mean Predicted Mean Observed Predicted Observed[0.000114,0.000301) 1660 0 0 0.4 0[0.000301,0.000676) 2272 0 0 1.08 1[0.000676,0.000729) 642 0.001 0 0.44 0[0.000729,0.000998) 2107 0.001 0.001 1.73 3
0.000998 909 0.001 0 0.91 0[0.001037,0.001834) 2123 0.001 0.001 2.68 3[0.001834,0.002451) 1512 0.002 0.003 3.3 4[0.002451,0.002643) 1006 0.002 0.003 2.49 3[0.002643,0.002961) 1441 0.003 0.002 3.83 3[0.002961,0.006629) 1505 0.005 0.005 8.13 8
4.1.3 Firth’s Correction
In table 4.1, the Renal Transplant and the Stroke/TIA variables have zero values. Here we face a
quasi-separation problem, in which the estimated coefficients have huge standard errors, and therefore
causes these variables not to be statistically significant (p-values near 1). So, an univariate Firth’s logistic
regression was run, with Renal Transplant and Stroke/TIA as independent variables (Table 4.6). This
quasi-separation problem did not arise when the categorization of Age, Diastolic Blood Pressure and
Fluoroscopy Time was performed.
Table 4.6: Logistic Regression and Firth’s Correction univariate analysis regarding β estimates, their standard errors (s.e.) and
their p-values.
Univariate Analysis
Variable
Logistic Regression Firth’s Logistic Regression
βˆ βˆ s.e. Wald Test
p-value
βˆ βˆ s.e. Wald’s
p-value
Likelihood Ratio
p-value
Renal Transplant -12.144 779.604 0.988 1.455 1.442 0.313 0.409
Stroke/TIA -15.219 815.797 0.985 -1.523 1.428 0.286 0.162
The p-values decrease as expected in both variables. As the Stroke/TIA variable has a p-value lower
than 0.25, this variable was included in a preliminary model (alongside with all variables with a p-value
less than 0.25). The selection method was the same used in the previous logistic regression. In the end,
Stroke/TIA is removed from the final model because is not statistically significant. The final model using
Firth’s correction contains the same variables as in the previous logistic regression, but with slightly
different values regarding the β estimates and their standard errors (Table 4.7). The AUC is 0.731 (Table
4.7) and the calibration plot was very similar too (not shown), compared to the previous LR.
38
Table 4.7: Firth’s Corrected Model. β coefficients, Odds Ratios, the corresponding 95% Confidence Intervals, p-values from the
Likelihood Ratio test, p-value from the Hosmer-Lemeshow test and AUC.
Variable βˆ OˆR
95% CI Likelihood Ratio
Hosmer AUC
Lower Higher p-value
Transradial Approach 0.156 1.168 0.468 2.633 0.723
0.934 0.731
Dyslipidemia 1.195 3.304 1.307 10.512 0.010
Age 65 0.778 2.177 0.973 5.254 0.058
Fluoroscopy Time10 -0.815 0.443 0.155 1.064 0.070
Diastolic Blood Pressure72 0.944 2.570 1.151 6.196 0.021
4.1.4 Treatment Effect Estimation (Odds Ratio)
The exposure to the Transradial or Transfemoral approach proved to be statistically non-significant (Table
4.4), and therefore does not contribute to the occurrence of peri-procedural Stroke/TIA. For anyone with
Dyslipidemia, the odds are 263% higher to have a peri-procedural Stroke/TIA. Similarly, the odds are
124% higher for anyone with Age superior to 65 and 165% higher to anyone with Diastolic Blood Pressure
superior to 72. The Fluoroscopy Time superior to 10 minutes is the only significant protector factor. If the
Fluoroscopy Time (in minutes) is superior to 10, the odds are 58.7% lower than if the Fluorsocopy Time
is lower than 10 minutes (Table 4.4).
4.2 Matching on the Propensity Score
Before matching, is clear that the treatment groups differ significantly regarding to some confounders and
other variables (i.e. variables with SMD>0.10) (Table 4.8). This make it impossible to obtain an unbiased
estimate comparing directly the outcomes of both groups. Our motivation is to create treatment groups
that are as homogeneous as possible through matching on the Propensity Score (PS). The balance of
variables that are suspected to influence the outcome (True Confounders and Potential Confounders) is
essential (Austin, 2011a).
The potential confounding variables were the ones identified before as independent predictors of the
outcome. The confounding variables were identified as the ones that are suspected to be associated with
the outcome (in univariate LR, p-value<0.25), associated with the treatment assignment (in univariate
LR, p-value<0.05), and the OR (regarding the exposure) is altered more than 10% when the variable
is added to the model containing only the exposure as independent variable. The variables associated
with the treatment assignment were identified as the ones that are independent predictors of the treatment
assignment (p-value < 0.05) in a multivariable logistic regression context. The identified subsets of
variables are displayed in Table 4.9.
39
Table 4.8: Standard Mean Difference (SMD) between Transradial and Transfemoral Group, before matching. Regarding four
groups of variables: True Confounders, Potential Confounders, Variables Associated with Treatment Assignment and Other
Variables.
Variable Before
Matching
True Confounders
Systolic Blood Presure 0.324
Fluoroscopy Time 0.131
Potential Confounders
Age 0.039
Dyslipidemia 0.008
Diastolic Blood Pressure 0.011
Fluoroscopy Time 0.131
Variables Associated with Treatment Assignment
Age 0.039
BMI 0.078
Diabetes Mellitus 0.017
Dyslipidemia 0.008
MI 0.159
PCI 0.063
CABG 0.384
Stroke/TIA 0.071
Moderate/Severe CRD 0.089
Renal Transplant 0.085
Interventional Procedure 0.148
Acute Coronary Syndrome 0.024
Aortic Valvulopathy 0.156
Systolic Blood Presure 0.324
Diastolic Blood Pressure 0.011
Number of Treated Segments 0.204
Fluoroscopy Time 0.131
Coronary Artery Disease Extension 0.195
Contrast Volume 0.157
Other Variables
Male Gender 0.017
Hypertension 0.03
Smoking 0.036
PAD 0.063
Non-CABG surgery 0.036
Number of Catheters Used 0.024
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Table 4.9: Variable Subsets under study.
Subset Variables
True Confounders Systolic Blood Pressure, Fluoroscopy Time.
Potential Confounders Age, Dyslipidemia, Systolic Blood Pressure,
Fluoroscopy Time.
Variables Associated with
Treatment Assignment
Age, BMI, Diabetes Mellitus, Dyslipidemia, MI,
PCI, CABG, Stroke/TIA, Moderate/Severe CRD,
Renal Transplant, Interventional Procedure, Acute
Coronary Syndrome, Aortic Valvulopathy, Systolic
Blood Pressure, Diastolic Blood Pressure, Coronary
Artery Disease Extension, Number of Treated
Segments, Fluoroscopy Time, Contrast Volume.
4.2.1 Propensity Score Model (Logistic Regression) and Matching
As stated in Section 3.5.3, there are four typical propensity score models. The variable subsets included in
these models as independent covariates are: 1. True Confounders, 2. Potential Confounders, 3. Variables
associated with the treatment assignment, 4. All observed variables. In this section, there were performed
four matchings, using propensity scores estimated by logistic regression with the four possible variable
subsets as independent covariates.
The categorized variables associated with the outcome and/or the treatment assignment were included
in the PS models as continuous. This because balancing a continuous variable will balance its categorized
analog, while the inverse is not true. Remind the balancing property ZX∣e(X) (Rubin and Rosenbaum,
1983).
In this context and throughout this work, the subjects subjected to Transradial Approach are the
”Treated” Group, and the subjects subjected to Transfemoral Approach are the ”Non-Treated” Group.
All matchings performed well, because all the variables targeted to be balanced in each matching were
balanced (SMD<0.10) (Table 4.10), i.e. the matching performed with the PS estimated by the PS model
with the True Confounders balanced the True Confounders between groups; the matching performed with
the PS estimated by the PS model with the Potential Confounders balanced the Potential Confounders
between groups and so on. This means that the PS estimates are consistent. Besides that, all the treated
subjects were matched in all matching circumstances, which signals that the common region of support is
not a problem. This was expected due to the great dimension of the Transfemoral Group compared to the
Transradial Group.
The PS models that are most reassuring are the ones that contain All Variables and the Variables
associated with Treatment Assignment, because these balanced all variables and not only the Confounders
(taking into account the SMD Table 4.10). Analysing the QQ-plots (Figure 4.4), the matchings improved
balance regarding Systolic BP, did not improve balance regarding Age and Diastolic BP (already balanced
before matching), and made it worse regarding to Fluoroscopy Time.
Although they are both efficient, the PS model with only the Variables associated with Treatment
Assignment, achieved a better balance regarding Potential and True Confounders which makes it a better
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Table 4.10: Standard Mean Difference (SMD) between Transradial and Transfemoral Group, before matching and after matching.
Propensity Scores used for matching were estimated by different propensity score models (True Confounders, Potential
Confounders, Variables associated with treatment assginment and all observed variables). Matching with Replacement, recurring
to NNM-CD with a 0.2 caliper.
Variable
After Matching
Variables within PS Model
Before
Matching
All Variables True
Confounders
Potential
Confounders
Variables
Associated
with
Treatment
Assignment
True Confounders
Systolic Blood Presure 0.324 0.07 0.006 0.322 0.03
Fluoroscopy Time 0.131 0.016 0.014 0.017 0.002
Potential Confounders
Age 0.039 0.02 0.118 0.063 0.002
Dyslipidemia 0.008 0.036 0.001 0.008 0.002
Diastolic Blood Pressure 0.011 0.024 0.105 0.028 0.033
Fluoroscopy Time 0.131 0.016 0.014 0.017 0.002
Variables Associated with Treatment Assignment
Age 0.039 0.02 0.118 0.063 0.002
BMI 0.078 0.025 0.024 0.056 0.043
Diabetes Mellitus 0.017 0.008 0.01 0.052 0.011
Dyslipidemia 0.008 0.036 0.001 0.008 0.002
MI 0.159 0.024 0.174 0.17 0.015
PCI 0.063 0.012 0.108 0.058 0.026
CABG 0.384 0.006 0.422 0.399 0.025
Stroke/TIA 0.071 0.006 0.071 0.077 0.008
Moderate/Severe CRD 0.089 0.006 0.064 0.131 0.002
Renal Transplant 0.085 <0.001 0.067 0.056 0.032
Interventional Procedure 0.148 0.011 0.243 0.265 0.047
Acute Coronary Syndrome 0.024 0.033 0.06 0.034 0.023
Aortic Valvulopathy 0.156 0.035 0.177 0.14 0.001
Systolic Blood Presure 0.324 0.07 0.006 0.322 0.03
Diastolic Blood Pressure 0.011 0.016 0.105 0.028 0.033
Number of Treated Segments 0.204 0.01 0.254 0.266 0.023
Fluoroscopy Time 0.131 0.016 0.014 0.017 0.002
Coronary Artery Disease Extension 0.195 0.01 0.252 0.265 0.024
Contrast Volume 0.157 0.003 0.254 0.273 0.028
Other Variables
Male Gender 0.017 0.003 0.088 0.013 0.003
Hypertension 0.03 0.001 0.001 0.084 0.001
Smoking 0.036 0.003 0.118 0.033 0.023
PAD 0.063 0.037 0.078 0.088 0.008
Non-CABG surgery 0.036 0.014 0.023 0.047 0.035
Number of Catheters Used 0.024 0.001 0.095 0.098 0.004
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(a) (b) (c)
Figure 4.4: QQ-plots before and after matching regarding Age, Systolic Blood Pressure, Diastolic Blood Pressure and Fluoroscopy
Time. (a) QQ-plots before matching. After matching, the LR PS model used to match is (b) the one containing all variables, (c)
the one containing all the variables associated with treatment assignment.
choice for further analysis. This choice was based on a careful analysis of the QQ-plots and the SMD
Table. The QQ-plots have more influence in this decision because they offer a more precise view of a
variable distribution by treatment group.
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4.2.2 Propensity Score Model and Matching: GAM Regression
Despite of the reasonable good balance achieved, there is still room for improvement. Applying GAMs
to estimate PS may improve even more the balance because it provides better estimates due to its
flexibility describing the true relationship between the independent covariates and the dependent one
(Treatment Assignment). The motivation to use GAMs is based on the fact that Systolic Blood Pressure
and Fluoroscopy Time are not linear with the treatment assignment logit (Figure 4.5), and therefore the
LR PS estimates are not trustworthy. Because of that, it is natural that GAMs used to estimate the PS
have, clearly, a superior predictive and discriminative power than LR models used before (Figure 4.6).
Figure 4.5: Univariate GAM functional forms regarding Age, BMI, Systolic BP, Diastolic BP, FLuoroscopy Time and Contrast
Volume as covariates and Transradial Approach as the dependent one. The functional form is represented by the filled lines and
the confidence intervals are represented by dashed lines.
New matching procedures were performed. Propensity scores were estimated based on two GAMs
with the following subset of independent covariates:
• All observed variables
• Variables associated with Treatment Assignment
All the matchings on the GAMs PS estimates provided SMD<0.10, for all variables (Table 4.11).
GAMs PS estimates provided more balanced matched samples, and therefore more successful matchings,
when compared to the matchings on the LR PS estimates. This improvement is not observed while
analysing the SMD Table (Table 4.11), but it is significant when looking to the QQ-plots (Figure 4.7).
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Figure 4.6: ROC plots and Calibration Plots regarding different PS models, with All Variables, All Variables (GAM), Variables
Associated with Treatment Assignment, Variables Associated with Treatment Assignment (GAM). AUC and its (CI) are shown
within each ROC plot.
Fluoroscopy Time and Systolic BP balance is very improved and Age balance is slightly improved, when
matching on the GAMs estimates.
Between the GAMs, the PS estimates that provide the most balanced matched samples are the ones
from the GAM with All Variables. Once more, this choice is based on a careful analysis on the SMD table
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Table 4.11: Standard Mean Difference (SMD) between Transradial and Transfemoral Group, after matching. Propensity Scores
used for matching estimated by different propensity score models (Variables associated with treatment assginment and All
observed variables), with and without GAM regression. Matching with Replacement, recurring to NNM-CD with a 0.2 caliper.
Variable
After Matching
Variables within PS model
All Variables All Variables
(GAM)
Var. Associated with
Treatment
Assignment
Var. Associated with
Treatment
Assignment (GAM)
True Confounders
Systolic Blood Presure 0.07 0.001 0.03 0.001
Fluoroscopy Time 0.016 0.022 0.002 0.084
Potential Confounders
Age 0.02 0.010 0.002 0.029
Dyslipidemia 0.036 0.006 0.002 0.028
Diastolic Blood Pressure 0.024 0.015 0.033 0.03
Fluoroscopy Time 0.016 0.022 0.002 0.084
Variables Associated with Treatment Assignment
Age 0.02 0.010 0.002 0.029
BMI 0.025 0.003 0.043 0.021
Diabetes Mellitus 0.008 0.001 0.011 0.043
Dyslipidemia 0.036 0.006 0.002 0.028
MI 0.024 0.010 0.015 0.021
PCI 0.012 0.022 0.026 0.006
CABG 0.006 0.034 0.025 0.023
Stroke/TIA 0.006 0.018 0.008 0.015
Moderate/Severe CRD 0.006 0.013 0.002 0.006
Renal Transplant <0.001 0.026 0.032 0.019
Interventional Procedure 0.011 0.024 0.047 0.061
Acute Coronary Syndrome 0.033 0.016 0.023 0.016
Aortic Valvulopathy 0.035 0.017 0.001 0.008
Systolic Blood Presure 0.07 0.001 0.03 0.001
Diastolic Blood Pressure 0.016 0.015 0.033 0.03
Number of Treated Segments 0.01 0.013 0.023 0.016
Fluoroscopy Time 0.016 0.022 0.002 0.084
Coronary Artery Disease Extension 0.01 0.011 0.024 0.017
Contrast Volume 0.003 0.030 0.028 0.052
Other Variables
Male Gender 0.003 0.006 0.003 0.019
Hypertension 0.001 0.016 0.001 0.013
Smoking 0.003 0.011 0.023 0.018
PAD 0.037 0.017 0.008 0.003
Non-CABG surgery 0.014 0.009 0.035 0.027
Number of Catheters Used 0.001 0.002 0.004 0.051
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(a) (b) (c) (d)
Figure 4.7: QQ-plots after matching regarding Age, Systolic Blood Pressure, Diastolic Blood Pressure and Fluoroscopy Time.
The PS estimates used for matching are from: (a) LR containing all variables (b) GAM containing all variables, (c) LR containing
the variables associated with treatment assignment, (d) GAM containing the variables associated with treatment assignment.
and the QQ-plots, because the two GAMs estimates perform in a very similar way. The main reason this
model was chosen was the fact that its estimates made Fluoroscopy Time slightly more balanced than the
other tested GAM with only the Variables Associated with Treatment Assignment.
4.2.3 Genetic Matching
Once again, in an attempt to improve balance, genetic matching was performed. The variable subsets used
in the Generalized Mahalanobis Distance were:
• All observed variables + LR PS estimates (Estimated from the PS model with All observed variables as covariates) ;
• All observed variables + GAM PS estimates;
• All variables associated with treatment; assignment + LR PS estimates (Estimated from the PS model with
All variables associated with treatment assignment as covariates) ;
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• All variables associated with treatment assignment + GAM PS estimates.
As stated before, the matching is not done based on the crude predicted probability of assignment, but
on the transformation log((1-x)/x). This transformation turns the crude estimate values distribution into a
more normal one. This is of extreme importance when genetic matching is executed, because the MD
perform better on normal distributed variables, that consequently will form a joint ellipsoidal distribution.
This way, all non-ellipsoidal distributions can be matched successfully because they can be matched
through the PS estimates. All variables present in this data set are non-normal except for Age, BMI,
Systolic BP and Diastolic BP. (Figure 4.8).
Figure 4.8: Histograms regarding Age, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, Fluoroscopy Time, Contrast
Volume and Number of Catheters Used. Bar Diagrams regarding Coronary Artery Decease and Number of Treated Segments,
All the PS transformations were very successful because they turned the crude PS estimates
distributions from all PS models into normal distributed ones. (Results only shown for LR PS estimates
with All Variables) (Figure 4.9).
In general, the genetic matchings were not significantly better than the matchings on the GAMs PS
estimates. The GMD weights relative to the various genetic matchings are in Table 4.13.
All the genetic matchings provided SMD<0.10, for all variables (Table 4.12). The genetic matching
using all variables plus the LR PS estimates and the genetic matching using the variables associated
with treatment assignment plus the GAM PS estimates provided unbalanced matched samples regarding
Systolic and Diastolic BP (Figure 4.10), so these matchings are discarded. The most successful genetic
matching was the one with all variables plus the GAM PS estimates. This one achieved a higher balance
on Age than any other.
The weights regarding each variable in each genetic matching are shown in Table 4.13.
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(a) (b)
Figure 4.9: Histograms of the: (a) Crude PS estimates and the (b) Transformed PS estimates. Estimated from the LR PS model
with All Variables.
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Table 4.12: Standard Mean Difference (SMD) between Transradial and Transfemoral Group, after Genetic matching (pop.
size=300). Propensity Scores estimated by different propensity score models with Variables associated with treatment assginment
and All observed variables, modeled by LR and GAM. Matching with Replacement, recurring to NNM-CD with a 0.2 caliper.
Loss Function: Maximum Kolmogorov-Smirnov statistic.
Variable
After Genetic Matching
Variable Subsets + PS estimates
All Variables All Variables
Var. Associated with
Treatment
Assignment
Var. Associated with
Treatment
Assignment
+ + + +
LR PS estimates GAM PS estimates LR PS estimates GAM PS estimates
True Confounders
Systolic Blood Presure 0.039 0.004 0.007 0.011
Fluoroscopy Time 0.011 0.005 0.009 0.021
Potential Confounders
Age 0.05 0.002 0.054 0.01
Dyslipidemia 0.044 0.022 0.001 0.017
Diastolic Blood Pressure 0.046 0.01 0.038 0.012
Fluoroscopy Time 0.011 0.005 0.009 0.021
Variables Associated with Treatment Assignment
Age 0.05 0.002 0.054 0.01
BMI 0.054 0.017 0.031 0.002
Diabetes Mellitus 0.002 0.014 0.001 0.024
Dyslipidemia 0.044 0.022 0.001 0.017
MI 0.013 <0.001 0.008 0.009
PCI 0.01 0.005 0.028 0.001
CABG 0.004 0.004 0.015 0.011
Stroke/TIA 0.02 0.045 0.043 0.017
Moderate/Severe CRD 0.022 0.018 <0.001 0.011
Renal Transplant 0.013 <0.001 0.026 0.019
Interventional Procedure 0.068 0.016 0.043 0.018
Acute Coronary Syndrome 0.057 0.021 0.04 <0.001
Aortic Valvulopathy 0.006 0.004 <0.001 0.007
Systolic Blood Presure 0.039 0.004 0.007 0.011
Diastolic Blood Pressure 0.046 0.01 0.038 0.012
Number of Treated Segments 0.001 0.016 0.035 0.016
Fluoroscopy Time 0.011 0.005 0.009 0.021
Coronary Artery Disease Extension 0.001 0.017 0.036 0.015
Contrast Volume 0.011 0.011 0.015 0.009
Other Variables
Male Gender 0.01 0.003 0.012 0.027
Hypertension 0.011 0.008 0.003 0.005
Smoking 0.037 0.004 0.001 0.011
PAD 0.002 0.009 0.017 0.027
Non-CABG surgery 0.013 0.031 0.004 0.028
Number of Catheters Used 0.004 <0.001 0.046 0.001
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(a) (b) (c) (d)
Figure 4.10: QQ-plots after matching regarding Age, Systolic Blood Pressure, Diastolic Blood Pressure and Fluoroscopy Time.
The matching method is: (a) genetic containing all variables plus the LR PS estimates, (b) genetic containing all variables plus
the GAM PS estimates, (c) genetic containing variables associated with treatment assignment plus the LR PS estimates, (d)
genetic containing variables associated with treatment assignment plus the GAM PS estimates.
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Table 4.13: Weights regarding Generalized Mahalanobis Distance (GMD), for every Genetic Matching performed [Variable
Subset + PS estimates]. SMD for every variable before matching.
Variable
All Variables All Variables
Var. Associated with
Treatment
Assignment
Var. Associated with
Treatment
Assignment
SMD Before
Matching
+ + + +
LR PS estimates GAM PS estimates LR PS estimates GAM PS estimates
Age 0.0 0.0 0.0 0.0 0.039
Male Gender 0.0 0.0 0.017
BMI 0.0 0.0 0.0 132.5 0.078
Diabetes Mellitus 0.0 0.0 0.0 0.0 0.017
Hypertension 0.0 0.0 0.03
Smoking 2.1 0.0 0.036
Dyslipidemia 0.0 0.0 0.0 0.0 0.008
MI 0.0 981.5 0.0 0.0 0.159
PCI 0.0 0.0 0.1 0.0 0.063
CABG 33.9 0.0 0.0 0.0 0.384
Stroke TIA prev 0.0 0.0 0.0 0.0 0.071
PAD 0.0 0.0 0.063
Non CABG Surgery 0.0 0.0 0.036
Moderate Severe CRD 0.0 0.0 208.2 0.0 0.089
Renal Transplant 0.0 572.2 0.0 0.0 0.085
Interventional Procedure 0.0 0.0 0.0 0.0 0.148
Acute Coronary Syndrome 0.0 0.0 0.0 428.7 0.024
Aortic Valvulopathy 0.0 0.0 110.2 0.0 0.156
Systolic Blood Pressure 0.0 0.0 142.9 2.9 0.324
Diastolic Blood Pressure 0.0 0.0 0.0 0.0 0.011
Coronary Artery Disease Ext. 22.5 0.0 0.195
Number of Treated Segments 785.7 0.0 0.0 0.0 0.204
Fluoroscopy Time 829.8 0.0 106.8 0.0 0.131
Contrast Volume 175.9 0.0 0.0 0.0 0.157
Number of Catheters Used 724.5 491.9 0.0 0.0 0.024
Propensity Score 848.3 797.9 907.0 995.1
52
4.2.4 Treatment Effect Estimation (Average Treatment Effect for the Treated)
Finally, there is the need to choose the best matching, in order to estimate the Average Treatment Effect
for the Treated (ATT). Comparing the SMD tables (Tables 4.10, 4.11, 4.12) and the QQ-plots (Figures 4.4,
4.7, 4.10), the matching that achieved higher balance on the confounders was the Genetic Matching with
all variables plus the GAM PS estimates. So, this will be the one used to estimate the ATT.
Table 4.14: Average Treatment Effect for the Treated and the respective Standard-Deviation (SD) estimated by Matching.
τˆATT SD(τˆATT ) p-value
H0 ∶ τATT = 0
0.000786 0.00087 0.36566
The Matching ATT estimate is 0.000786. This is not a significative difference because the p-value is
0.36566 (Table 4.14).
4.3 Stratification
The PS estimates used to stratify are fitted values of a GAM with all observed variables as dependent
covariates (Figure 4.11). Other PS models were tested like logistic regression with all variables, logistic
regression with the variables associated with exposure and a GAM with the variables associated with
exposure. The chosen PS estimates provide the best variable balance across all strata. Although there are
some SMD’s above 0.10, there are none above 0.25 (Table 4.15) which is the maximum acceptable value
(Guo and Fraser, 2009).
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(a) (b)
Figure 4.11: (a) PS estimates by Stratum, and by treatment group (Transradial coloured Blue and Transfemoral coloured Green ).
Stratum delimiters coloured Red. (b) Vioplots of the PS estimates of the two treatment groups. Vioplots are box-plot analogues
which depict, additionally, the density function (coloured Yellow).
In Stratum 1, there are 3 confounders unbalanced (Fluoroscopy Time, Age, Dyslipidemia). In Stratum
2, there are 2 confounders unbalanced (Fluoroscopy Time, Diastolic Blood Pressure, Dyslipidemia). In
Stratum 3 and 4, there are no confounders unbalanced. And in Stratum 5, 1 confounder unbalanced
(Dyslipidemia).
Besides the confounders, in Stratum 1, there are more 4 unbalanced variables (CABG, Moderate/Severe
CRD, PAD, Non-CABG surgery). In Stratum 2, more 2 unbalanced (Acute Coronary Syndrome, Aortic
Valvulopathy). In Stratum 3 and 4, no more unbalanced variables. In Stratum 5, 1 unbalanced variable
(Interventional Procedure).
A more efficient way to analyse the variable balance is to check for the QQ-plots. In this case, the
continuous confounding variables (Age, Diastolic BP, Systolic BP and Fluoroscopy Time) were analysed
through this method (Figure 4.12), all these variables seem to be reasonably balanced across all strata
except for the Systolic BP. This do not contradict the low SMD regarding this variable across all strata
(Table 4.15), because two different distributions may have equal means.
54
Table 4.15: Standard Mean Difference (SMD) between Transradial and Transfemoral Group, in each stratum. Propensity Scores
used estimated by a GAM with All observed variables as dependent covariates.
Variable
Stratification
(Interquintile Range)
Stratum1 Stratum2 Stratum3 Stratum4 Stratum5
(0 − 1st) (1st − 2nd) (2nd − 3rd) (3rd − 4th) (4th − 5th)
True Confounders
Systolic Blood Presure 0.066 0.012 0.073 0.02 0.094
Fluoroscopy Time 0.107 0.104 0.06 0.024 0.081
Potential Confounders
Age 0.106 0.056 0.016 0.093 0.042
Dyslipidemia 0.19 0.075 0.018 0.059 0.13
Diastolic Blood Pressure 0.08 0.148 0.055 0.061 0.008
Fluoroscopy Time 0.107 0.104 0.06 0.024 0.081
Variables Associated with Treatment Assignment
Age 0.106 0.056 0.016 0.093 0.042
BMI 0.014 0.047 0.038 0.004 0.064
Diabetes Mellitus 0.034 0.006 0.022 0.006 ¡0.001
Dyslipidemia 0.19 0.075 0.018 0.059 0.13
MI 0.067 0.034 0.026 0.052 0.028
PCI <0.001 0.021 0.014 0.006 0.018
CABG 0.211 0.051 0.027 0.029 0.036
Stroke/TIA 0.033 0.034 0.021 0.002 0.018
Moderate/Severe CRD 0.149 0.076 0.019 0.027 0.029
Renal Transplant 0.069 0.028 ∗ ∗ ∗ 0.033 ∗ ∗ ∗
Interventional Procedure 0.054 0.051 0.049 0.036 0.17
Acute Coronary Syndrome 0.055 0.151 0.01 0.092 0.076
Aortic Valvulopathy 0.012 0.134 0.017 0.026 0.053
Systolic Blood Presure 0.066 0.012 0.073 0.02 0.094
Diastolic Blood Pressure 0.08 0.148 0.055 0.061 0.008
Number of Treated Segments 0.07 0.08 0.009 0.06 0.066
Fluoroscopy Time 0.107 0.104 0.06 0.024 0.081
Coronary Artery Disease Extension 0.072 0.079 0.012 0.06 0.069
Contrast Volume 0.073 0.028 0.029 0.091 0.094
Other Variables
Male Gender 0.087 0.018 0.041 0.043 0.099
Hypertension 0.001 0.034 0.002 0.028 0.037
Smoking 0.055 0.031 0.015 0.04 0.099
PAD 0.139 0.034 0.071 0.086 0.067
Non-CABG surgery 0.128 0.006 0.03 0.028 0.009
Number of Catheters Used 0.096 0.096 0.061 0.042 0.074∗ ∗ ∗ Renal Transplant did not have subjects in both treatment groups, in stratum 3 and 5.
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Figure 4.12: QQ-plots after stratification regarding Age, Systolic Blood Pressure, Diastolic Blood Pressure and Fluoroscopy
Time, at each stratum. Stratum 1: Subjects within 0-1st quintile, Stratum 2: Subjects within 1st-2nd quintile, Stratum 3: Subjects
within 2nd-3rd quintile, Stratum 4: Subjects within 3rd-4th quintile, Stratum 5: Subjects within 4th-5th quintile.
4.3.1 Treatment Effect Estimation (Average Treatment Effect)
The Stratification Overall ATE estimate is -0.000386. This is not significant because the p-value is 0.50691
(Table 4.16).
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Table 4.16: Average Treatment Effect estimates (Stratum-specific and Overall) and its Standard-Deviation (SD), estimated by
Stratification .
Stratum-Specific Overall Overall p-value
τˆATE SD(τˆATE) τˆATE SD(τˆATE) H0 ∶ τATE = 0
Stratum1 -0.00217 0.00088
-0.000386 0.00058 0.50692
Stratum2 -0.00157 0.00078
Stratum3 -0.00222 0.00099
Stratum4 0.00280 0.00206
Stratum5 0.00125 0.00133
4.4 Inverse Probability Treatment Weighting
The PS estimates used in IPTW were the fitted values of the logistic regression with Variables Associated
with Treatment Assignment as covariates. This model was used because it provided sightly better variable
balances than the logistic regression with All Variables, in PS matching (Chapter 4.2). These great balance
achieved in Matching shows that these PS estimates are credible.
PS estimated by GAMs cannot be used in IPTW because there is no way to find the final τˆATE
variance and so, significance tests are not possible (Lunceford and Davidian, 2004).
4.4.1 Treatment Effect Estimation (ATE)
Table 4.17: Average Treatment Effect and its Standard-Deviation (SD) estimated by IPTW .
τˆATE SD(τˆATE) p-value
H0 ∶ τATE = 0
-0.000155 0.00029 0.59150
The IPTW ATE estimate is -0.000155. This is not significant because the p-value is 0.59150. (Table
4.17)
4.5 GLM and PS mixed approach: Covariate Adjustment
In an attempt to include all variables in the model, it was added to the final LR model obtained in 4.1.2,
a ”summary” variable. This variable is the PS estimate obtained from a logistic regression PS model
containing all the variables except for the ones already in the model (Dyslipidemia, Age, Fluoroscopy
Time and Diastolic Blood Pressure). The model is described in Table 4.18; and the ROC Curve and
Calibration Plot are displayed in Figure 4.13.
The PS estimate addition into the model does not provide any improvement, because the model’s
discriminative and predictive power remain roughly the same. This suggests that the variables included
through the PS are not valuable to explain the event occurrence. PS estimates were also obtained from a
GAM and introduced in the model, which returned very similar results.
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Table 4.18: LR Model with PS estimates as variable. β coefficients, Odds Ratios, its 95% confidence intervals, and the Wald Test
p-values.
Variable
β OR
95% CI
Wald p-value Hosmer AUC
Lower Higher
Transradial Approach 0.1243 1.132 0.454 2.825 0.790
0.997 0.731
Dyslipidemia 1.284 3.609 1.235 10.550 0.019
Age65 0.805 2.237 0.947 5.284 0.066
Fluoroscopy Time10 -0.886 0.412 0.151 1.126 0.085
Diastolic Blood Pressure72 0.965 2.625 1.098 6.273 0.030
100×PS Estimates -0.0013 0.999 0.957 1.042 0.954
(a) (b)
Figure 4.13: (a) ROC curve regarding model in Table. b) Calibration Plot regarding the Hosmer-Lemeshow Test applied to
model in Table 4.18
Table 4.19: Hosmer-Lemeshow predicted risk bins. For each bin: Mean predicted and mean observed events, total predicted and
total observed events. Regarding model in Table 4.18.
Bins Total Mean Predicted Mean Observed Predicted Observed[0.000115,0.000298) 1466 0 0 0.36 0[0.000298,0.000631) 1465 0 0.001 0.58 1[0.000631,0.000737) 1466 0.001 0 0.98 0[0.000737,0.000956) 1465 0.001 0.001 1.19 2[0.000956,0.001062) 1466 0.001 0.001 1.48 1[0.001062,0.001661) 1465 0.001 0.001 1.7 2[0.001661,0.002316) 1466 0.002 0.002 2.94 3[0.002316,0.002625) 1465 0.002 0.003 3.63 5[0.002625,0.002990) 1466 0.003 0.002 4.01 3[0.002990,0.007056] 1465 0.006 0.005 8.14 8
The Code used to produce the results in Chapter 4 is in the Appendices.
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Chapter 5
Discussion
It was possible to identify some variables associated with the occurrence of a peri-procedural Stroke/TIA,
within logistic regression. They were Age above 65 y, Dyslipidemia, higher Diastolic Blood Pressure
(>72 mmHg) and Fluoroscopy Time. All of the identified variables make sense being included in the
model. Relative do their younger counterparts, older people have a higher risk of all procedure-related
complications because of comorbidity, vascular stiffness and tortuosity and a high burden of vascular
disease. Dyslipidemia and high blood pressure, with no surprise, are important risk factors, also due to
their association with more advanced atherosclerotic disease (Donnan et al., 2008; Sacco et al., 1997).
Paradoxically, Fluoroscopy Time was the only identified protector factor. Fluoroscopy time is a surrogate
of higher procedure duration and vascular manipulation, and thus it is inverse association with neurologic
complications is apparently paradoxical. The reasons for this are not clear. This can be a proxy variable
- meaning that it is not in itself directly relevant, but can be related to unobservable or immeasurable
confounders - or simply a matter of statistical chance. It is arguable than, weather or not this variable
should have been kept in the final model.
There are some variables that would make sense too be on the final model as Hypertension,
Interventional Procedure, Aortic Valvulopathy, Acute Coronary Syndrome, Coronary Artery Disease
Extension, Number of Treated Segments, Contrast Volume, Diabetes mellitus and Smoking History.
Mostly, these variables are not in the model, because they are correlated with the ones included in it.
High Systolic BP is, almost, Hypertension synonym. The variables Interventional Procedure, Aortic
Valvulopathy, Acute Coronary Syndrome, Coronary Artery Disease Extension and Number of Treated
Segments are all indicators of the general health condition of the patient, which is associated with the
Age, Dyslipidemia and BP. The Smoking history and Diabetes mellitus are direct risk factors for the
occurrence of a Stroke/TIA (Donnan et al., 2008; Sacco et al., 1997).
One of the main drawbacks of these study were the low number of events (27), which jeopardized and
limited the quality of the model (Peduzzi et al., 1996). The validity of the logistic regression was verified
by checking the linearity of the variables with the outcome logit, and by so a GAM was not required
to model the data efficiently. There were some variables like Age and Fluoroscopy Time that were not
significant as continuous variables but proved their value to the model by being categorized. This means
that only major changes in these variables are worth being seen as risk factors (Mazumdar and Glassman,
2000).
As stated before, the low number of events harms the quality of the model because there is not
enough information being considered. One of the problems that comes with this is the Separation
59
Problem (Heinze and Schemper, 2002). The variables affected by this were the Renal Transplant and the
Stroke/TIA history. In fact, the Stroke/TIA history can be considered as a variable that can explain the
outcome variable (Sacco et al., 1997) and, if not included in the final model because of the Separation
problem, the final model is in risk of being misspecified. Although, it was not the case because the
Firth’s correction returned roughly the same model as the traditional logistic regression discussed in the
paragraphs above.
Returning to the main objective of this work, the logistic regression results pointed that Transradial
Approach is not a risk factor related to the ocurrence of peri-operational Stroke/TIA. This result is in
accordance with the literature (Ratib et al., 2013a; Raposo et al., 2015). It is noteworthy that only the
logistic regression enables us to separately identify different risk factors, contrary to the PS methodologies
(Austin, 2011a).
Following the traditional Logistic Regression, this work moved into the estimation of new kinds of
treatment effects besides the OR. One of them is the ATT, which is estimated based on the PS matching of
subjects. The best matching is the one which balances the most prognostically important variables and if
possible all the other variables, between treatment groups. Because of that, there is the need to search for
the PS estimates that satisfy us the most (Guo and Fraser, 2009).
There were obtained very diverse PS estimates from various PS models (Logistic Regression and
Generalized Additive Models), with different subsets of variables as independent covariates (True
Confounders, Potential Confounders, Variables Associated with Treatment Assignment and All). The
PS estimates that originated the best balance were the ones from the GAM PS model with all variables.
This is not surprising because the Fluoroscopy Time and Systolic Blood Pressure are not linear with the
treatment assignment logit, and so GAMs are a better fitting strategy (more predictive and discriminative
power obtained) (Woo et al., 2008). That is why, after matching with GAM PS estimates, Fluoroscopy
Time and Systolic Blood Pressure were the variables that improved more its balance between treatment
groups. This GAM PS estimates summarize these variables in a more efficient way, and so, the balance
regarding these variables improves.
The best subsets of variables to be included in the PS model were All and the ones Associated with
Treatment Assignment. This is expected because these subsets balance all variables and not only the
confounders. The subset with the Variables Associated with Treatment Assignment balances all variables
because the ones that are unbalanced before matching are present in this subset, in the end, all observed
variables stay balanced after matching.
In the search for a even better matching, Genetic Matching appears as a solid alternative (Diamond
and Sekhon, 2012). Generally, it produced slightly more successful matchings. This is expected because
it only matches on the variables if there is some advantage in doing so. If not, it continues to match on the
PS estimates only. The best genetic matching was the one with All variables plus the GAM PS estimates
(estimated from All variables as independent covariates). This is not a big surprise because GAM PS
estimates with all the variables had already been considered to provide the best matching among the
non-genetic matchings.
With no surprise the weights attributed to the PS estimates in all genetic matchings performed were
very high, which proves their value on matching (Diamond and Sekhon, 2012). There are few categorical
variables with weights different from zero, which demonstrates that the GMD does not perform well with
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this kind of variables. It is odd that there are some continuous non-normal distributed variables with high
weights. Maybe these continuous variables can adapt and form a joint ellipsoidal distribution more easily
than categorical ones, and this way form a more efficient GMD. It is noteworthy that there a lot more
weights equal to zero when genetic matching with GAM PS estimates is applied, i.e. there is not the need
to resort so heavily to the variables themselves to achieve the best possible balance (e.g. Fluoroscopy
Time). This reflects that these GAM PS estimates summarize way better the variables than the LR PS
estimates. The variables that are more imbalanced before matching are the ones that are more prone to be
weighted, unless these ones are efficiently represented by the respective PS estimate.
Still, genetic matching did not improve the balance as much as expected. This might have happened
because the genetic matching needed more iterations run to reach the maximum possible balance. An
interesting fact is that genetic matching can overcome the main weaknesses of the logistic regression PS
estimates by matching individually on the variables that are not linear with the treatment assignment logit
(Fluoroscopy Time and Systolic BP). This is proved when the logistic regression PS estimates based on
the Variables Associated with Treatment Assignment almost achieved the same level of balance as the
GAM PS estimates based on All Variables (in the genetic matching context). The expectation that the
genetic matchings with logistic regression PS estimates would provide roughly the same level of balance
between them was defrauded, as well as between the matching with GAM PS estimates. This may have to
do with the genetic matching random nature. That is why the weight matrixes are all so different among
the genetic matchings.
Overall the best matching achieved was the genetic matching with all variables plus the GAM PS
estimates. This led to ATT*=0.000786. The Approach used would not made any difference among the
Transradial Approach Group (”Treated Group”), regarding the occurrence of a peri-procedural Stroke/TIA.
This result is consistent with the literature (Raposo et al., 2015).
Regarding stratification, the PS estimates used to stratify were the ones that provided best balance
across strata. These were estimated from the GAM PS model with All Variables. The balance within each
stratum was not brilliant. Although there were no variables with SMD>0.25, there were a lot of variables
with SMD>10. Stratification is a coarser way of matching subjects, and because of that it is no surprise
that balance within strata is worse (Austin, 2011a).
Stratification ATE estimate is -0.000386 which means if all operated people were to change from
Transfemoral to Transradial Approach the population proportion who suffers a peri-procedural Stroke/TIA
is 0.000386 less. This difference is not significant.
To perform IPTW the logistic regression PS estimates based on Variables Associated with Treatment
Assignment were chosen, because it is not possible to estimate the estimator variance if the PS are
estimated by GAMs. IPTW ATE estimate is -0.000155 which means if all operated people were to change
from Transfemoral to Transradial Approach the population proportion who suffers a peri-procedural
Stroke/TIA is 0.000155 less. This difference is not significant.
The Covariate Adjustment provided roughly the same results as the previous logistic regressions
(traditional and Firth’s). This indicates that the variables summarized by the PS, in this context, do not
provide much information.
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Chapter 6
Conclusion
All the procedures applied in this work pointed to the same conclusion. The use of Transradial or
Transfemoral Approach did not influence the occurrence of periprocedural Stroke/TIA. This way, the
clinically preferential use of Transradial Approach can presumably be performed with little concerns
relative to periprocedural neurological complications related to this technique. This result is in accordance
with the literature (Hamon et al., 2007; Ratib et al., 2013b; Raposo et al., 2015).
Regarding the methodological issues, it was proved that GAMs provide PS estimates that origin more
successful matchings than logistic regression PS estimates, when the variables are not linear with the
treatment assignment logit. On the other hand, applying genetic matching can overcome these differences
by matching individually on these non-linear variables using the GMD. This conclusions about the
methodology reinforce previous results found in the literature that highlight the utility of GAMs in PS
estimation and its synergy with genetic matching (Hastie and Tibshirani, 1986; Woo et al., 2008).
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Other Work Accomplished
During the course of this work, the author had the opportunity to develop a ShinyR application (web
application framework for R). This application ”Propensity Scores: An application to Medicine” is
the first of its type to analyse in an automated way data through Propensity Score analysis (PS model
building, Matching, Genetic Matching, IPTW and Stratification). This application enables the data input
and, consequently its intuitive, reliable and time-saving analysis. It can be accessed through this link:
https ∶ //luis − garcez − ferreira.shinyapps.io/my app shiny 3/.
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Appendix A
Logistic Regression
l i b r a r y (ROCR)
l i b r a r y ( PredictABEL )
l i b r a r y ( mgcv )
l i b r a r y (pROC)
# ####DATA#####
d a t a 1 =read . csv2 ( ’ c a r d i o l o g i a 1 e 2 . csv ’ )
d a t a 1 =as . data . frame ( d a t a 1 )
names ( d a t a 1 )= c ( ”Age” ,
” Male Gender ” ,
”BMI” ,
” D i a b e t e s M e l l i t u s ” ,
” H y p e r t e n s i o n ” ,
” Smoking ” ,
” D y s l i p i d e m i a ” ,
”MI” ,
” PCI ” ,
”CABG” ,
” S t r o k e TIA prev ” ,
”PAD” ,
”Non CABG S u r g e r y ” ,
” Modera te S ev e r e CRD” ,
” Renal T r a n s p l a n t ” ,
” I n t e r v e n t i o n a l P r o c e d u r e ” ,
” Acute Coronary Syndrome ” ,
” A o r t i c V a l v u l o p a t h y ” ,
” S y s t o l i c Blood P r e s s u r e ” ,
” D i a s t o l i c Blood P r e s s u r e ” ,
” Coronary A r t e r y D i s e a s e E x t e n s i o n ” ,
”Number o f T r e a t e d Segments ” ,
” F l u o r o s c o p y Time min ” ,
” C o n t r a s t Volume ” ,
”Number o f C a t h e t e r s Used ” ,
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” T r a n s r a d i a l Approach ” , # t r e a t m e n t
” S t r o k e TIA outcome ” ) # outcome
# ##############CHECKING LOGIT LINEARITY ###############
par ( mfrow=c ( 2 , 3 ) )
y l im =c ( −2 ,2 )
gam=gam ( S t r o k e TIA outcome ˜ s ( Age ) , s u b s e t ( da ta1 , Age>27&Age<95) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =”Age” , y l im = yl im )
gam=gam ( S t r o k e TIA outcome ˜ s (BMI ) , s u b s e t ( da ta1 , BMI>17&BMI<45) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =”BMI” , y l im = yl im )
gam=gam ( S t r o k e TIA outcome ˜ s ( S y s t o l i c Blood P r e s s u r e ) ,
s u b s e t ( da ta1 , S y s t o l i c Blood P r e s s u r e <240) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” S y s t o l i c Blood P r e s s u r e ” , y l im = yl im )
gam=gam ( S t r o k e TIA outcome ˜ s ( D i a s t o l i c Blood P r e s s u r e ) ,
s u b s e t ( da ta1 , D i a s t o l i c Blood P r e s s u r e <100&D i a s t o l i c Blood P r e s s u r e >40) ,
f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” D i a s t o l i c Blood P r e s s u r e ” , y l im = yl im )
gam=gam ( S t r o k e TIA outcome ˜ s ( F l u o r o s c o p y Time min ) ,
s u b s e t ( da ta1 , F l u o r o s c o p y Time min<55) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” F l u o r o s c o p y Time ” , y l im = yl im )
gam=gam ( S t r o k e TIA outcome ˜ s ( C o n t r a s t Volume ) ,
s u b s e t ( da ta1 , C o n t r a s t Volume<400&C o n t r a s t Volume>10) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” C o n t r a s t Volume ” , y l im = yl im )
# ##############MINIMUM p−VALUE APPROACH###############
minp <− f u n c t i o n ( x , ybin , x c u t i n t ) {
tmp1 <− sapply ( s o r t ( unique ( x c u t i n t ) ) , f u n c t i o n ( x0 , x , yb in )
{
tmp <− c h i s q . t e s t (1 * ( x <= x0 ) , yb in )
t a b l <− t a b l e (1 * ( x > x0 ) , yb in )
r r <− ( ( t a b l [ 1 , 1 ] + 0 . 5 ) / ( ( t a b l [ 1 , 1 ] + 0 . 5 ) + ( t a b l [ 2 , 1 ] + 0 . 5 ) ) ) /
( ( t a b l [ 1 , 2 ] + 0 . 5 ) / ( ( t a b l [ 1 , 2 ] + 0 . 5 ) + ( t a b l [ 2 , 2 ] + 0 . 5 ) ) )
c ( x0 , tmp$ s t a t i s t i c , tmp$p . va lue , r r )
}
, x , yb in )
tmpl <− data . frame ( t ( tmp1 ) )
tmp1
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}
yb in <− S t r o k e TIA outcome
par ( mfrow=c ( 2 , 3 ) )
x = Age ; x c u t i n t <− 52 :68 ; c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ]
p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r Age” , y l a b =”p−v a l u e ” ,
c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) ) ; a b l i n e ( h =0 .1289 , l t y =3)
a b l i n e ( v =65 , l t y =3)
x = BMI ; x c u t i n t = 20 :40 ; c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ]
p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r BMI” , y l a b =”p−v a l u e ” ,
c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) ) ; a b l i n e ( h =0 .3090 , l t y =3)
a b l i n e ( v =32 , l t y =3)
x = S y s t o l i c Blood P r e s s u r e ; x c u t i n t =133:155
c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ] ; p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r S y s t o l i c Blood P r e s s u r e ” ,
y l a b =”p−v a l u e ” , c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) )
a b l i n e ( h =0 .1022 , l t y = 3 ) ; a b l i n e ( v =147 , l t y =3)
x = D i a s t o l i c Blood P r e s s u r e ; x c u t i n t = 60 :100
c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ] ; p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r D i a s t o l i c Blood P r e s s u r e ”
y l a b =”p−v a l u e ” , c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) ) ;
a b l i n e ( h =0 .0456 , l t y = 3 ) ; a b l i n e ( v =72 , l t y =3)
x = F l u o r o s c o p y Time min ; x c u t i n t =5:16
c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ] ; p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r F l u o r o s c o p y Time ” ,
y l a b =”p−v a l u e ” , c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) )
a b l i n e ( h = 0 . 1 6 , l t y = 3 ) ; a b l i n e ( v =10 , l t y =3)
x = C o n t r a s t Volume ; x c u t i n t =80:119
c u t p o i n t s =minp ( x , ybin , x c u t i n t ) [ 1 , ] ; p v a l u e s =minp ( x , ybin , x c u t i n t ) [ 3 , ]
p l o t ( c u t p o i n t s , p v a l u e s , x l a b =” c u t p o i n t f o r C o n t r a s t Volume ” ,
y l a b =”p−v a l u e ” , c o l =” r e d ” , pch =19 , y l im =c ( 0 , 1 ) )
a b l i n e ( h = 0 . 3 7 , l t y = 3 ) ; a b l i n e ( v =92 , l t y =3)
# ############## LOGISTIC REGRESSION FINAL ###############
Age 65=Age>65
BMI 32=BMI>32
S y s t o l i c Blood P r e s s u r e 147= S y s t o l i c Blood P r e s s u r e >147
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D i a s t o l i c Blood P r e s s u r e 72= D i a s t o l i c Blood P r e s s u r e >72
F l u o r o s c o p y Time min 10= F l u o r o s c o p y Time min>10
m1=glm ( S t r o k e TIA outcome ˜ T r a n s r a d i a l Approach + D y s l i p i d e m i a + Age 65 +
S y s t o l i c Blood P r e s s u r e 72 + D i a s t o l i c Blood P r e s s u r e 147 +
Acute Coronary Syndrome + F l u o r o s c o p y Time min 10 , f a mi ly = binomial )
summary (m1)
m2=update (m1 , S t r o k e TIA outcome ˜ .− S y s t o l i c Blood P r e s s u r e 147)
summary (m2)
m3=update (m2 , S t r o k e TIA outcome ˜ .−Acute Coronary Syndrome )
summary (m3)
a t t a c h ( d a t a 1 )
model1=glm ( S t r o k e TIA outcome ˜ T r a n s r a d i a l Approach+ D y s l i p i d e m i a + Age 65 +
D i a s t o l i c Blood P r e s s u r e 72 + F l u o r o s c o p y Time min 10 ,
f a mi ly = binomial )
summary ( model1 )
# s u b j e c t s used t o f i t t h e model
s u b j e c t s 1 =which ( i s . na ( F l u o r o s c o p y Time min )==FALSE
&i s . na ( D i a s t o l i c Blood P r e s s u r e )==FALSE)
# ############## C a l i b r a t i o n P l o t ###############
detach ( d a t a 1 )
a x i s =c ( 0 , 0 . 0 0 6 1 )
cOutcome =27
par ( mfrow=c ( 1 , 2 ) )
p l o t C a l i b r a t i o n ( data= d a t a 1 [ s u b j e c t s 1 , ] , cOutcome =27 , p r e d R i s k =model1 $ f i t t e d ,
g r ou ps =10 , r a n g e a x i s = a x i s )
# ##############ROC c u r v e ###############
plotROC ( data= d a t a 1 [ s u b j e c t s 1 , ] , cOutcome=cOutcome ,
p r e d r i s k =model1 $ f i t t e d . v a l u e s )
roc1 = r o c ( d a t a 1 [ , cOutcome ] , model1 $ f i t t e d )
c i ( r oc1 )
p l o t ( r oc1 )
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Appendix B
Firth’s Correction
l i b r a r y ( l o g i s t f )
# ##############UNIVARIATE FIRTH ’ S LOGISTIC REGRESSION###############
m= l o g i s t f ( S t r o k e TIA outcome ˜ Renal T r a n s p l a n t , f a mi ly = binomial )
summary (m)
m= l o g i s t f ( S t r o k e TIA outcome ˜ S t r o k e TIA prev , f a mi ly = binomial )
summary (m)
# ############## FINAL FIRTH ’ S LOGISTIC REGRESSION###############
m11= l o g i s t f ( S t r o k e TIA outcome ˜ T r a n s r a d i a l Approach + D y s l i p i d e m i a
+ Age 65 + S y s t o l i c Blood P r e s s u r e 147
+ D i a s t o l i c Blood P r e s s u r e 72
+ Acute Coronary Syndrome + F l u o r o s c o p y Time min 10
+ S t r o k e TIA prev , f a mi ly = binomial )
summary ( m11 )
m22=update ( m11 , S t r o k e TIA outcome ˜ .− S y s t o l i c Blood P r e s s u r e 147)
summary ( m22 )
m33=update ( m22 , S t r o k e TIA outcome ˜ .−Acute Coronary Syndrome )
summary ( m33 )
m44=update ( m33 , S t r o k e TIA outcome ˜ .− S t r o k e TIA prev )
summary ( m44 )
model1=m44
# ###############CALIBRATION PLOT################
detach ( d a t a 1 )
a x i s =c ( 0 , 0 . 0 0 6 1 )
cOutcome =27
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par ( mfrow=c ( 1 , 2 ) )
p l o t C a l i b r a t i o n ( data= d a t a 1 [ s u b j e c t s 1 , ] , cOutcome =27 ,
p r e d R i s k =model1 $ p r e d i c t ,
g r ou ps =10 , r a n g e a x i s = a x i s )
# ###############ROC CURVE################
cOutcome =27
plotROC ( data= d a t a 1 [ s u b j e c t s 1 , ] , cOutcome=cOutcome ,
p r e d r i s k =model1 $ p r e d i c t )
r oc1 = r o c ( d a t a 1 [ , cOutcome ] , model1 $ f i t t e d )
c i ( r oc1 )
p l o t ( r oc1 )
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Appendix C
Propensity Score Matching
l i b r a r y ( ”mgcv” )
l i b r a r y ( ”ROCR” )
l i b r a r y ( ” Matching ” )
l i b r a r y ( ” memisc ” )
l i b r a r y ( ” t a b l e o n e ” )
l i b r a r y ( ”MKmisc” )
l i b r a r y ( ” l e a p s ” )
source ( ” f u n c t i o n s . R” ,TRUE)
# c o n t a i n s f u n c t i o n s :
#MATCH, MATCH graph , MATCH balance , AUCcalib ,
# gen match model , MATCH g e n e t i c ,
# d e s c r i b e d i n Appendix ” F u n c t i o n s ”
# ##############TESTING CONFOUNDING###############
d a t a 2 =cbind ( da ta1 , Age 65 ,BMI 32 , S y s t o l i c Blood P r e s s u r e 147 ,
D i a s t o l i c Blood P r e s s u r e 72 ,
F l u o r o s c o p y Time min 10)
a t t a c h ( d a t a 2 )
n var= l e n g t h ( names ( d a t a 2 )) −2
u n i o u t = l a p p l y ( names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ] , f u n c t i o n ( var ) {
formula <− as . formula ( p a s t e ( ” S t r o k e TIA outcome ˜ ” , var ) )
r e s . l o g i s t <− glm ( formula , f a mi ly = binomial )
c ( summary ( r e s . l o g i s t ) $ c o e f [ 2 , 1 ] , summary ( r e s . l o g i s t ) $ c o e f [ 2 , 4 ] ) } )
names ( u n i o u t )= names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ]
u n i o u t
u n i exp= l a p p l y ( names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ] , f u n c t i o n ( var ) {
formula = as . formula ( p a s t e ( ” T r a n s r a d i a l Approach ˜ ” , var ) )
r e s . l o g i s t = glm ( formula , f a mi ly = binomial )
c ( summary ( r e s . l o g i s t ) $ c o e f [ 2 , 1 ] ,
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summary ( r e s . l o g i s t ) $ c o e f [ 2 , 4 ] ) } )
names ( u n i exp )= names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ]
u n i exp
u n i o u t p l u s exp=glm ( S t r o k e TIA outcome ˜ T r a n s r a d i a l Approach , f a mi ly = binomial )
c o e f = u n i o u t p l u s exp$ c o e f [ 2 ]
summary ( u n i o u t p l u s exp )
u n i o u t p l u s exp var= l a p p l y ( names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ] , f u n c t i o n ( var ) {
formula= as . formula ( p a s t e ( ” S t r o k e TIA outcome ˜ T r a n s r a d i a l Approach +” , var ) )
r e s . l o g i s t = glm ( formula , f a mi ly = binomial )
summary ( r e s . l o g i s t ) $ c o e f [ 2 , 1 ] } )
names ( u n i o u t p l u s exp var )= names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ]
u n i o u t p l u s exp var
c o l names=c ( ” Outcome ˜ Var Beta ” ,
”p−v a l u e ” ,
” Exposure ˜ Var Beta ” ,
”p−v a l u e ” ,
” Outcome ˜ Exposure Beta ” ,
” Outcome ˜ Exposure +Var ( Beta r e g a r d i n g Exposure ) ” ,
” Beta V a r i a t i o n (%) ” ,
”OR” ,
” Outcome ˜ Exposure +Var (OR r e g a r d i n g Exposure ) ” ,
”OR V a r i a t i o n (%) ” )
matrix=matrix ( nrow=n var , nco l =10 ,
dimnames= l i s t ( names ( d a t a 2 ) [ c ( 1 : 2 5 , 2 8 : 3 2 ) ] , c o l names ) )
f o r ( i i n c ( 1 : 3 0 ) ) { matrix [ i , 1 ] = u n i o u t [ [ i ] ] [ 1 ]
matrix [ i , 2 ] = u n i o u t [ [ i ] ] [ 2 ]
matrix [ i , 3 ] = u n i exp [ [ i ] ] [ 1 ]
matrix [ i , 4 ] = u n i exp [ [ i ] ] [ 2 ]
matrix [ i , 5 ] = c o e f
matrix [ i , 6 ] = u n i o u t p l u s exp var [ [ i ] ]
matrix [ i , 7 ] = ( matrix [ i , 5 ] − matrix [ i , 6 ] ) / matrix [ i , 5 ] *100
matrix [ i , 8 ] = exp ( c o e f )
matrix [ i , 9 ] = exp ( u n i o u t p l u s exp var [ [ i ] ] )
matrix [ i , 1 0 ] = ( matrix [ i , 8 ] − matrix [ i , 9 ] ) / matrix [ i , 8 ] * 100}
matrix
m a t r i x 1 =matrix [ which ( matrix [ , 2 ] <0 . 2 5 ) , ]
m a t r i x 1
m a t r i x 2 = m a t r i x 1 [ which ( m a t r i x 1 [ , 4 ] <0 . 0 5 ) , ]
m a t r i x 2
w r i t e . matrix ( matrix , f i l e =” c o n f o u n d i n g ” , sep =” , ” )
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# ##############BALANCE BEFORE MATCHING###############
t a b b a s e l i n e = Crea t eTab leOne ( v a r s = names ( d a t a 2 ) ,
f a c t o r V a r s = names ( d a t a 2 ) [ c ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 1 0 ,
1 1 , 1 2 , 1 3 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 2 8 , 2 9 ,
3 0 , 3 1 , 3 2 ) ] ,
s t r a t a = ” T r a n s r a d i a l Approach ” ,
data= d a t a 2 )
p r i n t ( t a b b a s e l i n e , smd=TRUE)
par ( mfrow=c ( 1 , 1 ) )
index t r e a t e d =which ( T r a n s r a d i a l Approach ==1)
index c o n t r o l =which ( T r a n s r a d i a l Approach ==0)
names ( d a t a 1 )
qqplot ( Age [ index t r e a t e d ] , Age [ index c o n t r o l ] , y l im =c ( 0 , 1 0 0 ) , x l im =c ( 0 , 1 0 0 ) ,
x l a b =”Age among T r a n s r a d i a l Group ” , y l a b =”Age among T r a n s f e m o r a l Group ” ,
main=” Be fo re Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)
qqplot ( S y s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
S y s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 5 0 , 2 5 0 ) , x l im =c ( 5 0 , 2 5 0 ) ,
x l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
main=” Be fo re Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)
qqplot ( D i a s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
D i a s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 3 0 , 1 4 0 ) , x l im =c ( 3 0 , 1 4 0 ) ,
x l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
main=” Be fo re Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)
qqplot ( F l u o r o s c o p y Time min [ index t r e a t e d ] ,
F l u o r o s c o p y Time min [ index c o n t r o l ] ,
y l im =c ( 0 , 9 0 ) , x l im =c ( 0 , 9 0 ) ,
x l a b =” F l u o r o s c o p y Time among T r a n s r a d i a l Group ” ,
y l a b =” F l u o r o s c o p y Time among T r a n s f e m o r a l Group ” , ,
main=” Be fo re Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)
# ##############PS MODEL (GLM w i t h ALL VARIABLES ) AND MATCHING###############
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ps a l l c o n t =glm ( T r a n s r a d i a l Approach ˜ Age+Male Gender+BMI+ D i a b e t e s M e l l i t u s +
H y p e r t e n s i o n +Smoking+ D y s l i p i d e m i a +MI+PCI+CABG+ S t r o k e TIA prev+
PAD+Non CABG S u r g e r y +Modera te S ev e r e CRD+ Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e +Acute Coronary Syndrome+
A o r t i c V a l v u l o p a t h y + S y s t o l i c Blood P r e s s u r e +
D i a s t o l i c Blood P r e s s u r e + Coronary A r t e r y D i s e a s e E x t e n s i o n +
Number o f T r e a t e d Segments+ F l u o r o s c o p y Time min+
C o n t r a s t Volume+Number o f C a t h e t e r s Used ,
f a mi ly = binomial )
# s u b j e c t s used t o f i t t h e PS model
s u b j e c t s a l l =which ( i s . na ( Age+Male Gender+BMI+ D i a b e t e s M e l l i t u s +
H y p e r t e n s i o n +Smoking+ D y s l i p i d e m i a +MI+PCI+
CABG+ S t r o k e TIA prev+
PAD+Non CABG S u r g e r y +Modera te S ev e r e CRD+
Renal T r a n s p l a n t + I n t e r v e n t i o n a l P r o c e d u r e +
Acute Coronary Syndrome+ A o r t i c V a l v u l o p a t h y +
S y s t o l i c Blood P r e s s u r e + D i a s t o l i c Blood P r e s s u r e +
Coronary A r t e r y D i s e a s e E x t e n s i o n +
Number o f T r e a t e d Segments+ F l u o r o s c o p y Time min+
C o n t r a s t Volume+Number o f C a t h e t e r s Used )==FALSE)
# e v a l u a t e PS model
AUCcalib ( ps a l l cont , s u b j e c t s a l l , 26 , da t a1 , 1 , ” A l l V a r i a b l e s ” ) #ROC c u r v e
l egend ( 0 . 4 , 0 . 4 , l egend =” 0 .718 \n ( 0 . 7 0 9 −0 . 7 2 7 ) ” , cex = 1 . 3 , b t y = ” n ” )
AUCcalib ( ps a l l cont , s u b j e c t s a l l , 26 , da t a1 , 2 ) # hosmer
AUCcalib ( ps a l l cont , s u b j e c t s a l l , 26 , da t a1 , 3 , ” A l l v a r i a b l e s ” ) #Hosmer
# match ing
match=MATCH( ps a l l cont , s u b j e c t s a l l )
summary ( match ) # match
# a c c e s s i n g b a l a n c e a f t e r match ing
MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 3 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 4 , match )
MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
summary ( match )
#PS t r a n s f o r m a t i o n
h i s t o g r a m ( l o g ( (1 − ps a l l c o n t $ f i t t e d ) / ps a l l c o n t $ f i t t e d ) , b r e a k s =100 ,
x l a b =” Trans fo rmed PS e s t i m a t e s ” )
h i s t o g r a m ( ps a l l c o n t $ f i t t e d , b r e a k s =100 ,
x l a b =” Crude PS e s t i m a t e s ” )
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# g e n e t i c match ing
X=cbind ( ( d a t a 2 [ , c ( 1 : 2 5 ) ] ) [ s u b j e c t s a l l , ] ,
l o g ( (1 − ps a l l c o n t $ f i t t e d ) / ps a l l c o n t $ f i t t e d ) )
ps a l l c o n t gen w =
gen match model ( X=X , s u b j e c t s a l l ,
w= diag ( ps a l l c o n t gam gen w$ Weight . matrix ) )
match=MATCH g e n e t i c (X, s u b j e c t s a l l , ps a l l c o n t gen w )
ps a l l c o n t gen=MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 3 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 4 , match )
summary ( match ) # b e s t match ing o v e r a l l
# ##########PS MODEL (GAM w i t h ALL VARIABLES ) AND MATCHING####################
ps a l l c o n t gam=gam ( T r a n s r a d i a l Approach ˜ s ( Age )+ Male Gender+s (BMI)+
D i a b e t e s M e l l i t u s + H y p e r t e n s i o n +Smoking+
D y s l i p i d e m i a +MI+PCI+CABG+ S t r o k e TIA prev+
PAD+Non CABG S u r g e r y +Modera te S ev e r e CRD+ Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e +Acute Coronary Syndrome+
A o r t i c V a l v u l o p a t h y +s ( S y s t o l i c Blood P r e s s u r e )+
s ( D i a s t o l i c Blood P r e s s u r e )+
Coronary A r t e r y D i s e a s e E x t e n s i o n +
Number o f T r e a t e d Segments+
s ( F l u o r o s c o p y Time min )+ s ( C o n t r a s t Volume )+
Number o f C a t h e t e r s Used ,
f a mi ly = binomial )
# e v a l u a t e PS model
AUCcalib ( ps a l l c o n t gam , s u b j e c t s a l l , 26 , da t a1 , 1 , ” A l l V a r i a b l e s (GAM) ” )
l egend ( 0 . 4 , 0 . 4 , l egend =” 0 .750 \n ( 0 . 7 4 1 −0 . 7 5 9 ) ” , cex = 1 . 3 , b t y = ” n ” )
AUCcalib ( ps a l l c o n t gam , s u b j e c t s a l l , 26 , da t a1 , 2 )
AUCcalib ( ps a l l c o n t gam , s u b j e c t s a l l , 26 , da t a1 , 3 , ” A l l v a r i a b l e s (GAM) ” )
y l im =c ( −2 ,2 )
# match ing
match=MATCH( ps a l l c o n t gam , s u b j e c t s a l l )
# a c e s s i n g b a l a n c e
MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a2 , 3 , match )
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MATCH graph ( s u b j e c t s a l l , da t a2 , 4 , match )
summary ( match )
# g e n e t i c match ing
X=cbind ( ( d a t a 2 [ , c ( 1 : 2 5 ) ] ) [ s u b j e c t s a l l , ] ,
l o g ( (1 − ps a l l c o n t gam$ f i t t e d ) / ps a l l c o n t gam$ f i t t e d ) )
ps a l l c o n t gam gen w = gen match model ( X=X , s u b j e c t s a l l ,
w=ps a l l c o n t gam gen w$ Weight . matrix )
match=MATCH g e n e t i c (X, s u b j e c t s a l l , ps a l l c o n t gam gen w )
ps a l l c o n t gen=MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 3 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 4 , match )
# ###########PS MODEL (GLM w i t h V a r i a b l e s A s s o c i a t e d w i t h T r e a t m e n t A s s i g n m e n t )
# AND MATCHING ############
summary ( ps a l l c o n t )
ps exp s i g 1 =update ( ps a l l cont , ˜ .− Coronary A r t e r y D i s e a s e E x t e n s i o n )
summary ( ps exp s i g 1 )
ps exp s i g 2 =update ( ps exp s ig1 , ˜ .− Smoking )
summary ( ps exp s i g 2 )
ps exp s i g 3 =update ( ps exp s ig2 , ˜ .−Non CABG S u r g e r y )
summary ( ps exp s i g 3 )
ps exp s i g 4 =update ( ps exp s ig3 , ˜ .−PAD)
summary ( ps exp s i g 4 )
ps exp s i g 5 =update ( ps exp s ig4 , ˜ .− H y p e r t e n s i o n )
summary ( ps exp s i g 5 )
ps exp s i g 6 =update ( ps exp s ig5 , ˜ .−Male Gender )
summary ( ps exp s i g 6 )
ps exp s i g c o n t =ps exp s i g 6
s u b j e c t s ps exp s i g c o n t =which ( i s . na ( Age + BMI + D i a b e t e s M e l l i t u s +
D y s l i p i d e m i a + MI + PCI + CABG + S t r o k e TIA prev +
Modera te S ev e r e CRD + Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e + Acute Coronary Syndrome +
A o r t i c V a l v u l o p a t h y + S y s t o l i c Blood P r e s s u r e +
D i a s t o l i c Blood P r e s s u r e +
Number o f T r e a t e d Segments +
F l u o r o s c o p y Time min + C o n t r a s t Volume +
Number o f C a t h e t e r s Used )==FALSE)
#PS model e v a l u a t i o n
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AUCcalib ( ps exp s i g cont , s u b j e c t s ps exp s i g cont , 26 , da ta1 , 1 ,
” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment ” )
l egend ( 0 . 4 , 0 . 4 , l egend =” 0 .718 \n ( 0 . 7 0 8 −0 . 7 2 7 ) ” , cex = 1 . 3 , b t y = ” n ” )
AUCcalib ( ps exp s i g cont , s u b j e c t s ps exp s i g cont , 26 , da ta1 , 2 ,
” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment ” )
AUCcalib ( ps exp s i g cont , s u b j e c t s ps exp s i g cont , 26 , da ta1 , 3 ,
” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment ” )
# match ing
match=MATCH( ps exp s i g cont , s u b j e c t s ps exp s i g c o n t )
# A c c e s s i n g b a l a n c e
MATCH b a l a n c e ( s u b j e c t s ps exp s i g cont , da t a2 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 1 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 2 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 3 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 4 , match )
h i s t o g r a m ( F l u o r o s c o p y Time min [ s u b j e c t s ps exp s i g c o n t ] )
h i s t o g r a m ( l o g ( (1 − ps exp s i g c o n t $ f i t t e d ) / ps exp s i g c o n t $ f i t t e d ) , b r e a k s =100 ,
x l a b =” Trans fo rmed PS e s t i m a t e s ” )
h i s t o g r a m ( ps exp s i g c o n t $ f i t t e d , b r e a k s =100 ,
x l a b =” Crude PS e s t i m a t e s ” )
# g e n e t i c match ing
X=cbind ( ( d a t a 2 [ c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] ) [ s u b j e c t s ps exp s i g cont , ] ,
l o g ( (1 − ps exp s i g c o n t $ f i t t e d ) / ps exp s i g c o n t $ f i t t e d ) )
ps exp s i g c o n t gen w = gen match model ( X=X , s u b j e c t s ps exp s i g cont ,
w=ps exp s i g c o n t gen w$ Weight . matrix )
match=MATCH g e n e t i c (X, s u b j e c t s a l l , ps exp s i g c o n t gen w )
ps a l l c o n t gen=MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 3 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 4 , match )
# ###########PS MODEL (GAM w i t h V a r i a b l e s A s s o c i a t e d w i t h T r e a t m e n t A s s i g n m e n t )
# AND MATCHING ############
ps exp s i g c o n t gam=gam ( T r a n s r a d i a l Approach ˜ s ( Age )+ s (BMI)+ D i a b e t e s M e l l i t u s +
D y s l i p i d e m i a +MI+PCI+CABG+ S t r o k e TIA prev+
Modera te S ev e r e CRD+ Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e +
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Acute Coronary Syndrome+ A o r t i c V a l v u l o p a t h y +
s ( S y s t o l i c Blood P r e s s u r e )+
s ( D i a s t o l i c Blood P r e s s u r e )+
Number o f T r e a t e d Segments+
s ( F l u o r o s c o p y Time min )+ s ( C o n t r a s t Volume )+
Number o f C a t h e t e r s Used ,
f a mi ly = binomial )
#PS model e v a l u a t i o n
AUCcalib ( ps exp s i g c o n t gam , s u b j e c t s ps exp s i g cont ,
26 , da ta1 , 1 , ” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment \n (GAM) ” )
l egend ( 0 . 4 , 0 . 4 , l egend =” 0 .750 \n ( 0 . 7 4 1 −0 . 7 5 8 ) ” , cex = 1 . 3 , b t y = ” n ” )
AUCcalib ( ps exp s i g c o n t gam , s u b j e c t s ps exp s i g cont ,
26 , da ta1 , 2 , ” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment \n (GAM) ” )
AUCcalib ( ps exp s i g c o n t gam , s u b j e c t s ps exp s i g cont ,
26 , da ta1 , 3 , ” V a r i a b l e s Assoc . w i th T r e a t m e n t Ass ignment \n (GAM) ” )
# match ing
match=MATCH( ps exp s i g c o n t gam , s u b j e c t s ps exp s i g c o n t )
# A c c e s s i n g b a l a n c e
MATCH b a l a n c e ( s u b j e c t s ps exp s i g cont , da t a2 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 1 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 2 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 3 , match )
MATCH graph ( s u b j e c t s ps exp s i g cont , da t a2 , 4 , match )
summary ( match )
# g e n e t i c match ing
X=cbind ( ( d a t a 2 [ c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] ) [ s u b j e c t s ps exp s i g cont , ] ,
l o g ( (1 − ps exp s i g c o n t gam$ f i t t e d ) / ps exp s i g c o n t gam$ f i t t e d ) )
ps exp s i g c o n t gam gen w =
gen match model ( X=X , s u b j e c t s ps exp s i g cont ,
w=ps exp s i g c o n t gam gen w$ Weight . matrix )
match=MATCH g e n e t i c (X, s u b j e c t s a l l , ps exp s i g c o n t gam gen w )
ps a l l c o n t gen=MATCH b a l a n c e ( s u b j e c t s a l l , da t a2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 1 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 2 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 3 , match )
MATCH graph ( s u b j e c t s a l l , da t a1 , 4 , match )
82
# ##############CHECKING LOGIT LINEARITY REGARDING TREATMENT###############
par ( mfrow=c ( 2 , 3 ) )
y l im =c ( −2 ,2 )
gam=gam ( T r a n s r a d i a l Approach ˜ s ( Age ) , s u b s e t ( da ta1 , Age>27&Age<95) ,
f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =”Age” , y l im = yl im )
gam=gam ( T r a n s r a d i a l Approach ˜ s (BMI ) , s u b s e t ( da ta1 , BMI>17&BMI<45) ,
f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =”BMI” , y l im = yl im )
gam=gam ( T r a n s r a d i a l Approach ˜ s ( S y s t o l i c Blood P r e s s u r e ) ,
s u b s e t ( da ta1 , S y s t o l i c Blood P r e s s u r e <240) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” S y s t o l i c Blood P r e s s u r e ” , y l im = yl im )
gam=gam ( T r a n s r a d i a l Approach ˜ s ( D i a s t o l i c Blood P r e s s u r e ) ,
s u b s e t ( da ta1 , D i a s t o l i c Blood P r e s s u r e <100&D i a s t o l i c Blood P r e s s u r e >40) , f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” D i a s t o l i c Blood P r e s s u r e ” , y l im = yl im )
gam=gam ( T r a n s r a d i a l Approach ˜ s ( F l u o r o s c o p y Time min ) ,
s u b s e t ( da ta1 , F l u o r o s c o p y Time min<55) ,
f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” F l u o r o s c o p y Time ” , y l im = yl im )
gam=gam ( T r a n s r a d i a l Approach ˜ s ( C o n t r a s t Volume ) ,
s u b s e t ( da ta1 , C o n t r a s t Volume<400&C o n t r a s t Volume>10) ,
f a mi ly = binomial )
p l o t ( gam , se =T , y l a b =” f ( x ) ” , x l a b =” C o n t r a s t Volume ” , y l im = yl im )
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Appendix D
Stratification
l i b r a r y ( mgcv )
l i b r a r y ( ” v i o p l o t ” )
l i b r a r y ( ” t a b l e o n e ” )
source ( ” f u n c t i o n s . R” ,TRUE)
# c o n t a i n s f u n c t i o n s :
#STRATA , STRATA balance , STRATA graph
# d e s c r i b e d i n Appendix ” F u n c t i o n s ”
# ##############PS MODEL FOR STRATIFICATION ###############
#PS model
a t t a c h ( d a t a 1 )
ps a l l c o n t gam=gam ( T r a n s r a d i a l Approach ˜ s ( Age )+ Male Gender+s (BMI)+
D i a b e t e s M e l l i t u s + H y p e r t e n s i o n +Smoking+ D y s l i p i d e m i a +
MI+PCI+CABG+ S t r o k e TIA prev+PAD+Non CABG S u r g e r y +
Modera te S ev e r e CRD+ Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e +Acute Coronary Syndrome+
A o r t i c V a l v u l o p a t h y +s ( S y s t o l i c Blood P r e s s u r e )+
s ( D i a s t o l i c Blood P r e s s u r e )+
Coronary A r t e r y D i s e a s e E x t e n s i o n +
Number o f T r e a t e d Segments+s ( F l u o r o s c o p y Time min )+
s ( C o n t r a s t Volume )+ Number o f C a t h e t e r s Used ,
f a mi ly = binomial )
s u b j e c t s a l l =which ( i s . na ( Age+Male Gender+BMI+ D i a b e t e s M e l l i t u s +
H y p e r t e n s i o n +Smoking+ D y s l i p i d e m i a +MI+PCI+CABG+
S t r o k e TIA prev+PAD+Non CABG S u r g e r y +
Modera te S ev e r e CRD+ Renal T r a n s p l a n t +
I n t e r v e n t i o n a l P r o c e d u r e +Acute Coronary Syndrome+
A o r t i c V a l v u l o p a t h y + S y s t o l i c Blood P r e s s u r e +
D i a s t o l i c Blood P r e s s u r e +
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Coronary A r t e r y D i s e a s e E x t e n s i o n +
Number o f T r e a t e d Segments+
F l u o r o s c o p y Time min+ C o n t r a s t Volume+
Number o f C a t h e t e r s Used )==FALSE)
model=ps a l l c o n t gam
s u b j e c t s = s u b j e c t s a l l
# a t t r i b u t e s u b j e c t s t o s t r a t a
s t r a t a =STRATA( da ta1 , s u b j e c t s , model )
# ##############BALANCE ACROSS STRATA###############
#SMD t a b l e s t o each s t r a t u m
w r i t e . csv (STRATA b a l a n c e ( da ta1 , s u b j e c t s , s t r a t u m 1 =1 , s t r a t a ) ,
” s t r a t u m 1 b a l a n c e ” )
w r i t e . csv (STRATA b a l a n c e ( da ta1 , s u b j e c t s , s t r a t u m 1 =2 , s t r a t a ) ,
” s t r a t u m 2 b a l a n c e ” )
w r i t e . csv (STRATA b a l a n c e ( da ta1 , s u b j e c t s , s t r a t u m 1 =3 , s t r a t a ) ,
” s t r a t u m 3 b a l a n c e ” )
w r i t e . csv (STRATA b a l a n c e ( da ta1 , s u b j e c t s , s t r a t u m 1 =4 , s t r a t a ) ,
” s t r a t u m 4 b a l a n c e ” )
w r i t e . csv (STRATA b a l a n c e ( da ta1 , s u b j e c t s , s t r a t u m 1 =5 , s t r a t a ) ,
” s t r a t u m 5 b a l a n c e ” )
sum ( s t r a t a = = 1 ) ; sum ( s t r a t a = = 2 ) ; sum ( s t r a t a = = 3 ) ; sum ( s t r a t a = = 4 ) ; sum ( s t r a t a = = 5 ) ;
par ( mfrow=c ( 4 , 1 ) )
par ( mfrow=c ( 1 , 1 ) )
s t r a t a =STRATA( da ta1 , s u b j e c t s , model )
#qq− p l o t s f o r each s t r a t a and each v a r i a b l e ( f o r s t r a t u m 1)
STRATA graph ( da ta1 , s u b j e c t s , s t r a t u m 1 =1 , s t r a t a , g raph =1)
STRATA graph ( da ta1 , s u b j e c t s , s t r a t u m 1 =1 , s t r a t a , g raph =2)
STRATA graph ( da ta1 , s u b j e c t s , s t r a t u m 1 =1 , s t r a t a , g raph =3)
STRATA graph ( da ta1 , s u b j e c t s , s t r a t u m 1 =1 , s t r a t a , g raph =4)
# ############## STRATIFICATION REPRESENTATION###############
ps=ps a l l c o n t gam$ f i t t e d
p l o t ( ps [ which ( t r e a t e d ==1) ] ˜ c ( 1 : l e n g t h ( ps [ which ( t r e a t e d = = 1 ) ] ) ) ,
x l im =c ( 0 , l e n g t h ( s u b j e c t s ) ) ,
y l im =c ( 0 , 1 ) ,
c o l =4 ,
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x l a b =” S u b j e c t Index ” ,
y l a b =”PS E s t i m a t e s ” )
p o i n t s ( ps [ which ( t r e a t e d ==0) ] ˜ c ( ( l e n g t h ( ps [ which ( t r e a t e d = = 1 ) ] ) + 1 ) :
l e n g t h ( s u b j e c t s ) ) , c o l =3)
q u a n t i l e s = q u a n t i l e ( ps , c ( 0 , 0 . 2 , 0 . 4 , 0 . 6 , 0 . 8 , 1 ) )
a b l i n e ( h= q u a n t i l e s , c o l =2 , lwd =2)
l egend ( ” t o p r i g h t ” , c ( ” T r a n s r a d i a l ” , ” T r a n s f e m o r a l ” ) ,
c o l =c ( 4 , 3 ) , pch =1 , cex = 0 . 8 , pt . cex =1 , b t y =” o ” )
# v i o p l o t
v i o p l o t ( ps [ which ( t r e a t e d = = 1 ) ] , ps [ which ( t r e a t e d = = 0 ) ] , c o l =7 ,
names=c ( ” T r a n s r a d i a l Group ” , ” T r a n s f e m o r a l Group ” ) ,
# y l a b =”PS E s t i m a t e s ” ,
# main=”Common S u p p o r t ” ,
yl im =c ( 0 , 1 ) )
t i t l e ( y l a b =”PS E s t i m a t e s ” )
a b l i n e ( h= q u a n t i l e s , c o l =2 , lwd =2)
# ##############ATE ESTIMATION###############
outcome= S t r o k e TIA outcome [ s u b j e c t s ]
t r e a t e d = T r a n s r a d i a l Approach [ s u b j e c t s ]
# s t r a t u m s p e c i f i c s ATE
a t e 1 =mean ( outcome [ which ( t r e a t e d ==1&s t r a t a ==1)] ) −
mean ( outcome [ which ( t r e a t e d ==0&s t r a t a = = 1 ) ] )
a t e 2 =mean ( outcome [ which ( t r e a t e d ==1&s t r a t a ==2)] ) −
mean ( outcome [ which ( t r e a t e d ==0&s t r a t a = = 2 ) ] )
a t e 3 =mean ( outcome [ which ( t r e a t e d ==1&s t r a t a ==3)] ) −
mean ( outcome [ which ( t r e a t e d ==0&s t r a t a = = 3 ) ] )
a t e 4 =mean ( outcome [ which ( t r e a t e d ==1&s t r a t a ==4)] ) −
mean ( outcome [ which ( t r e a t e d ==0&s t r a t a = = 4 ) ] )
a t e 5 =mean ( outcome [ which ( t r e a t e d ==1&s t r a t a ==5)] ) −
mean ( outcome [ which ( t r e a t e d ==0&s t r a t a = = 5 ) ] )
ATE=mean ( c ( a t e1 , a t e2 , a t e3 , a t e4 , a t e 5 ) )
# ##############VARIANCE###############
# s t r a t u m s p e c i f i c v a r i a n c e
sd s t r a t u m = f u n c t i o n ( t r e a t e d 1 , outcome1 , s t r a t a 1 , s t r a t u m 1 ){
s u b j e c t s s t r a t u m =which ( s t r a t a 1 == s t r a t u m 1 )
s u b j e c t s s t r a t u m 1=which ( t r e a t e d 1 ==1&s t r a t a 1 == s t r a t u m 1 )
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s u b j e c t s s t r a t u m 0=which ( t r e a t e d 1 ==0&s t r a t a 1 == s t r a t u m 1 )
n s t r a t u m t r e a t e d = l e n g t h ( s u b j e c t s s t r a t u m 1)
n s t r a t u m c o n t r o l = l e n g t h ( s u b j e c t s s t r a t u m 0)
y 1 j = mean ( outcome1 [ s u b j e c t s s t r a t u m 1 ] )
y 0 j = mean ( outcome1 [ s u b j e c t s s t r a t u m 0 ] )
va r1 =(1 / n s t r a t u m t r e a t e d ) *
sum ( ( ( t r e a t e d 1 [ s u b j e c t s s t r a t u m ] * outcome1 [ s u b j e c t s s t r a t u m ]) − y 1 j ) ˆ 2 )
va r0 =(1 / n s t r a t u m c o n t r o l ) *
sum ( ( ( ( 1 − t r e a t e d 1 [ s u b j e c t s s t r a t u m ] ) * outcome1 [ s u b j e c t s s t r a t u m ]) − y 0 j ) ˆ 2 )
var s t r a t u m = va r1 / n s t r a t u m t r e a t e d + va r0 / n s t r a t u m c o n t r o l
re turn ( var s t r a t u m )
}
# o v e r a l l v a r i a n c e
var ATE= f u n c t i o n ( n s t r a t a 1 , v a r s 1 ){
i f ( n s t r a t a 1 == l e n g t h ( v a r s 1 ) ) { re turn (1 / ( n s t r a t a 1 ˆ 2 ) *sum ( v a r s 1 ) ) }
}
v a r s =c ( sd s t r a t u m ( t r e a t e d , outcome , s t r a t a , 1 ) ,
sd s t r a t u m ( t r e a t e d , outcome , s t r a t a , 2 ) ,
sd s t r a t u m ( t r e a t e d , outcome , s t r a t a , 3 ) ,
sd s t r a t u m ( t r e a t e d , outcome , s t r a t a , 4 ) ,
sd s t r a t u m ( t r e a t e d , outcome , s t r a t a , 5 ) )
varATE=var ATE( 5 , v a r s )
sdATE= s q r t ( varATE )
# ##############ATE ESTIMATION AND SIGNIFICANCE ###############
#p− v a l u e
2* (1−pnorm ( abs (ATE / sdATE ) ) )
# e s t i m a t i o n summary
matrix ( c ( a t e1 , a t e2 , a t e3 , a t e4 , a t e5 , s q r t ( v a r s [ 1 ] ) , s q r t ( v a r s [ 2 ] ) ,
s q r t ( v a r s [ 3 ] ) , s q r t ( v a r s [ 4 ] ) , s q r t ( v a r s [ 5 ] ) ) , 5 , 2 ,
dimnames= l i s t ( c ( ” 1 ” , ” 2 ” , ” 3 ” , ” 4 ” , ” 5 ” ) , c ( ”ATE” , ”SD ” ) ) )
matrix ( c ( ATE, sdATE , ATE / sdATE , pnorm (ATE / sdATE ) ) , 4 , 1 ,
dimnames= l i s t ( c ( ” O v e r a l l ATE” , ” sd ATE” , ”ATE / sdATE” , ”p−v a l u e ” ) ,
c ( ”OVERALL” ) ) )
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Appendix E
IPTW
source ( ” f u n c t i o n s . R” , TRUE)
# c o n t a i n s f u n c t i o n s :
#IPTW ATE , H beta1 , E b e t a b e t a i n v e r s e 1 , IPTW i v a r i a n c e 1 , IPTW t o t a l
# d e s c r i b e d i n Appendix ” F u n c t i o n s ”
#ATE e s t i m a t i o n
a t e ip tw =IPTW ATE( da ta1 , s u b j e c t s ps exp s i g , ps exp s i g c o n t )
# V a r i a n c e
H beta = H b e t a 1 ( da ta1 , s u b j e c t s ps exp s i g , ps exp s i g c o n t )
E b e t a b e t a i n v e r s e =E b e t a b e t a i n v e r s e 1 ( da ta1 , s u b j e c t s ps exp s i g ,
ps exp s i g c o n t )
IPTW i v a r i a n c e = IPTW i v a r i a n c e 1 ( ps exp s i g cont , a t e iptw ,
da ta1 , s u b j e c t s ps exp s i g , 4 ,
H beta , E b e t a b e t a i n v e r s e )
var IPTW=IPTW t o t a l ( da ta1 , s u b j e c t s ps exp s i g , ps exp s i g cont ,
a t e iptw , H beta , E b e t a b e t a i n v e r s e )
s q r t ( var IPTW)
#p− v a l u e
a t e ip tw / s q r t ( var IPTW)
2*pnorm ( a t e ip tw / s q r t ( var IPTW ) )
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Appendix F
Functions
# ##############MATCHING###############
# normal match ing
MATCH= f u n c t i o n ( model , s u b j e c t s ){
s e t . s e ed ( 1 )
ps match ing = Match (Y= S t r o k e TIA outcome [ s u b j e c t s ] ,
Tr= T r a n s r a d i a l Approach [ s u b j e c t s ] ,
X= l o g ( (1 −model$ f i t t e d ) / model$ f i t t e d ) ,
t i e s =FALSE ,
e s t i m a n d =”ATT” ,
c a l i p e r = 0 . 2 0 ,
r e p l a c e =TRUE,
d i s t a n c e . t o l e r a n c e = 1e−50
)
ps match ing
}
# w e i g h t m a t r i x used i n g e n e t i c match ing
gen match model= f u n c t i o n (X, s u b j e c t s ){
GenMatch ( T r a n s r a d i a l Approach [ s u b j e c t s ] , X, e s t i m a n d =”ATT” , M=1 ,
pop . s i z e = 500 , f i t . f unc =” p v a l s ” , t i e s =FALSE) #KS t e s t
}
# g e n e t i c match ing
MATCH g e n e t i c = f u n c t i o n (X, s u b j e c t s ,w){
s e t . s e ed ( 1 )
ps match ing = Match (Y= S t r o k e TIA outcome [ s u b j e c t s ] ,
Tr= T r a n s r a d i a l Approach [ s u b j e c t s ] , X= X,
t i e s =FALSE ,
e s t i m a n d =”ATT” ,
r e p l a c e =TRUE,
Weight . matrix=w
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)
ps match ing
}
# match ing b a l a n c e ( qq− p l o t s )
MATCH graph = f u n c t i o n ( s u b j e c t s , data complete , graph , ps match ing ){
data complete =data complete [ s u b j e c t s , ]
data=data complete
index t r e a t e d =ps match ing $ index . t r e a t e d
index c o n t r o l =ps match ing $ index . c o n t r o l
i f ( g raph ==1){
qqplot ( data $Age [ index t r e a t e d ] ,
data $Age [ index c o n t r o l ] ,
y l im =c ( 0 , 1 0 0 ) , x l im =c ( 0 , 1 0 0 ) ,
x l a b =”Age among T r a n s r a d i a l Group ” ,
y l a b =”Age among T r a n s f e m o r a l Group ” ,
main=” A f t e r Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==2){
qqplot ( data $ S y s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
data $ S y s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 5 0 , 2 5 0 ) , x l im =c ( 5 0 , 2 5 0 ) ,
x l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
main=” A f t e r Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==3){
qqplot ( data $ D i a s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
data $ D i a s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 3 0 , 1 4 0 ) , x l im =c ( 3 0 , 1 4 0 ) ,
x l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
main=” A f t e r Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==4){ qqplot ( data $ F l u o r o s c o p y Time min [ index t r e a t e d ] ,
data $ F l u o r o s c o p y Time min [ index c o n t r o l ] ,
y l im =c ( 0 , 9 0 ) , x l im =c ( 0 , 9 0 ) ,
x l a b =” F l u o r o s c o p y Time among T r a n s r a d i a l Group ” ,
y l a b =” F l u o r o s c o p y Time among T r a n s f e m o r a l Group ” ,
main=” A f t e r Matching ” )
a b l i n e ( a =0 , b =1 , c o l =2)}
}
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# match ing b a l a n c e (SMD t a b l e )
MATCH b a l a n c e = f u n c t i o n ( s u b j e c t s , data complete , ps match ing ){
data complete =data complete [ s u b j e c t s , ]
data=data complete [ c ( ps match ing $ index . t r e a t e d , ps match ing $ index . c o n t r o l ) , ]
t a b b a s e l i n e ps match ing =
Crea t eTab leOne ( v a r s = names ( data complete ) ,
f a c t o r V a r s = names ( data complete ) [ c ( 2 , 4 , 5 , 6 , 7 , 8 , 9 ,
1 0 , 1 1 , 1 2 , 1 3 , 1 4 ,
1 5 , 1 6 , 1 7 , 1 8 , 2 8 ,
2 9 , 3 0 , 3 1 , 3 2 ) ] ,
s t r a t a =” T r a n s r a d i a l Approach ” ,
data=data )
re turn ( p r i n t ( t a b b a s e l i n e ps matching , smd=TRUE ) )
}
# ##############MODEL EVALUATION###############
#AUC and C a l i b r a t i o n p l o t model
AUCcalib= f u n c t i o n ( model1 , s u b j e c t s 1 , outcome1 , da ta11 , o p t i o n 1 , t i t l e ){
i f ( o p t i o n 1 ==1){
plotROC ( data= d a t a 1 1 [ s u b j e c t s 1 , ] , cOutcome=outcome1 ,
p r e d r i s k =model1 $ f i t t e d . v a l u e s , p l o t t i t l e = t i t l e )
}
i f ( o p t i o n 1 ==2){
re turn ( HLgof . t e s t ( model1 $ f i t t e d ,
d a t a 1 [ , outcome1 ] [ s u b j e c t s 1 ] ) )
}
i f ( o p t i o n 1 ==3){
p l o t C a l i b r a t i o n ( data= d a t a 1 1 [ s u b j e c t s 1 , ] ,
cOutcome=outcome1 , p r e d R i s k =model1 $ f i t t e d ,
g r ou ps =10 , r a n g e a x i s =c ( 0 , 1 ) , p l o t t i t l e = t i t l e )}
}
# ############## STRATIFICATION ###############
# s t r a t a c l a s s i f i c a t i o n
STRATA= f u n c t i o n ( da ta11 , s u b j e c t s 1 , model1 ){
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d a t a 1 1 = d a t a 1 1 [ s u b j e c t s , ]
t r e a t e d = T r a n s r a d i a l Approach [ s u b j e c t s ]
ps=model1 $ f i t t e d
q u a n t i l e s = q u a n t i l e ( ps , p r o b s =c ( 0 , 0 . 2 0 , 0 . 4 0 , 0 . 6 0 , 0 . 8 0 , 1 ) )
i f ( l e n g t h ( ps )==dim ( d a t a 1 1 ) [ 1 ] ) {
s t r a t a =NULL
f o r ( i i n 1 : l e n g t h ( s u b j e c t s 1 ) )
{ i f ( ps [ i ]< q u a n t i l e s [ 2 ] ) { s t r a t a [ i ]=1}
i f ( ps [ i ]> q u a n t i l e s [ 2 ]&ps [ i ]< q u a n t i l e s [ 3 ] ) { s t r a t a [ i ]=2}
i f ( ps [ i ]> q u a n t i l e s [ 3 ]&ps [ i ]< q u a n t i l e s [ 4 ] ) { s t r a t a [ i ]=3}
i f ( ps [ i ]> q u a n t i l e s [ 4 ]&ps [ i ]< q u a n t i l e s [ 5 ] ) { s t r a t a [ i ]=4}
i f ( ps [ i ]> q u a n t i l e s [ 5 ] ) { s t r a t a [ i ]=5}
}}
re turn ( s t r a t a )
}
# b a l a n c e a c r o s s s t r a t a ( qq− p l o t s )
STRATA graph = f u n c t i o n ( data comple te1 , s u b j e c t s 1 , s t r a t u m 1 , s t r a t a 1 , g raph ){
data=data comple t e1 [ s u b j e c t s 1 , ]
t r e a t e d 1 =data $ T r a n s r a d i a l Approach
index t r e a t e d =which ( s t r a t a 1 == s t r a t u m 1&t r e a t e d 1 ==1)
index c o n t r o l =which ( s t r a t a 1 == s t r a t u m 1&t r e a t e d 1 ==0)
i f ( g raph ==1){
qqplot ( data $Age [ index t r e a t e d ] , data $Age [ index c o n t r o l ] , y l im =c ( 0 , 1 0 0 ) ,
x l im =c ( 0 , 1 0 0 ) ,
x l a b =”Age among T r a n s r a d i a l Group ” ,
y l a b =”Age among T r a n s f e m o r a l Group ” ,
main= p a s t e ( ” S t r a t u m ” , s t r a t u m 1 , sep =” ” ) )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==2){
qqplot ( data $ S y s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
data $ S y s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 5 0 , 2 5 0 ) , x l im =c ( 5 0 , 2 5 0 ) ,
x l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” S y s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
main= p a s t e ( ” S t r a t u m ” , s t r a t u m 1 , sep =” ” ) )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==3){
qqplot ( data $ D i a s t o l i c Blood P r e s s u r e [ index t r e a t e d ] ,
data $ D i a s t o l i c Blood P r e s s u r e [ index c o n t r o l ] ,
y l im =c ( 3 0 , 1 4 0 ) , x l im =c ( 3 0 , 1 4 0 ) ,
x l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s r a d i a l Group ” ,
y l a b =” D i a s t o l i c Blood P r e s s u r e among T r a n s f e m o r a l Group ” ,
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main= p a s t e ( ” S t r a t u m ” , s t r a t u m 1 , sep =” ” ) )
a b l i n e ( a =0 , b =1 , c o l =2)}
i f ( g raph ==4){ qqplot ( data $ F l u o r o s c o p y Time min [ index t r e a t e d ] ,
data $ F l u o r o s c o p y Time min [ index c o n t r o l ] ,
y l im =c ( 0 , 9 0 ) , x l im =c ( 0 , 9 0 ) ,
x l a b =” F l u o r o s c o p y Time among T r a n s r a d i a l Group ” ,
y l a b =” F l u o r o s c o p y Time among T r a n s f e m o r a l Group ” ,
main= p a s t e ( ” S t r a t u m ” , s t r a t u m 1 , sep =” ” ) )
a b l i n e ( a =0 , b =1 , c o l =2)}
}
# b a l a n c e a c r o s s s t r a t a (SMD t a b l e s )
STRATA b a l a n c e = f u n c t i o n ( data complete , s u b j e c t s 1 , s t r a t u m 1 , s t r a t a 1 ){
data complete =data complete [ s u b j e c t s , ]
data=data complete [ which ( s t r a t u m 1 == s t r a t a 1 ) , ]
t a b b a s e l i n e ps match ing =
Crea t eTab leOne ( v a r s = names ( data complete ) ,
f a c t o r V a r s = names ( data complete ) [ c ( 2 , 4 , 5 , 6 , 7 , 8 , 9 , 1 0 , 1 1 ,
1 2 , 1 3 , 1 4 , 1 5 , 1 6 , 1 7 , 1 8
s t r a t a =” T r a n s r a d i a l Approach ” , data=data )
re turn ( p r i n t ( t a b b a s e l i n e ps matching , smd=TRUE ) )
}
# ##############IPTW###############
#IPTW v a r i a n c e e s t i m a t i o n
H b e t a 1 = f u n c t i o n ( da ta11 , s u b j e c t s 1 , model11 ){
d a t a 6 6 = cbind ( rep ( 1 , l e n g t h ( s u b j e c t s 1 ) ) ,
d a t a 1 1 [ s u b j e c t s 1 , ] [ , c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] )
Y= S t r o k e TIA outcome [ s u b j e c t s 1 ]
Z= T r a n s r a d i a l Approach [ s u b j e c t s 1 ]
e=model11 $ f i t t e d
n = dim ( d a t a 6 6 ) [ 1 ]
W = t ( d a t a 6 6 )
sum=0
f o r ( i i n 1 : n ){
sum = sum + ( Z [ i ] *Y[ i ] * (1− e [ i ] ) / e [ i ] + (1−Z [ i ] ) *Y[ i ] * e [ i ] / (1− e [ i ] ) ) * W[ , i ]
}
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re turn ( as . matrix ( ( 1 / n ) *sum ) )
}
E b e t a b e t a i n v e r s e 1 = f u n c t i o n ( da ta11 , s u b j e c t s 1 , model11 ){
d a t a 6 6 = cbind ( rep ( 1 , l e n g t h ( s u b j e c t s 1 ) ) ,
d a t a 1 1 [ s u b j e c t s 1 , ] [ , c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] )
e=model11 $ f i t t e d
n = dim ( d a t a 6 6 ) [ 1 ]
W = t ( d a t a 6 6 )
sum=0
f o r ( i i n ( 1 : n ) ) {
sum = sum + e [ i ] * (1− e [ i ] ) * W[ , i ] %*% t (W[ , i ] )
}
re turn ( as . matrix (1 / n*sum ) )
}
IPTW i v a r i a n c e 1 = f u n c t i o n ( model11 , i p tw e s t i m a t e 1 , da ta11 ,
s u b j e c t s 1 , index1 , H be ta11 , E b e t a b e t a i n v e r s e 1 ){
d a t a 6 6 = cbind ( rep ( 1 , l e n g t h ( s u b j e c t s 1 ) ) ,
d a t a 1 1 [ s u b j e c t s 1 , ] [ , c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] )
Y= S t r o k e TIA outcome [ s u b j e c t s 1 ]
Z= T r a n s r a d i a l Approach [ s u b j e c t s 1 ]
e=model11 $ f i t t e d
n = dim ( d a t a 6 6 ) [ 1 ]
W = t ( d a t a 6 6 )
p a r t 1 = Z [ in de x1 ] *Y[ i nd ex 1 ] / e [ i nd ex 1 ]
p a r t 2 = (1−Z [ in de x1 ] ) *Y[ i nd ex 1 ] / (1− e [ i nd ex 1 ] )
p a r t 3 = ip tw e s t i m a t e 1
p a r t 4 = ( Z [ in de x1 ] − e [ i nd ex 1 ] )%*%
( t (H b e t a 1 1 )%*%E b e t a b e t a i n v e r s e 1%*%W[ , i nd ex 1 ] )
re turn ( p a r t 1 −p a r t 2 −p a r t 3 − p a r t 4 )
}
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IPTW t o t a l = f u n c t i o n ( da ta11 , s u b j e c t s 1 , model11 ,
i p tw e s t i m a t e 1 , H be ta11 , E b e t a b e t a i n v e r s e 1 ){
d a t a 6 6 =cbind ( rep ( 1 , l e n g t h ( s u b j e c t s 1 ) ) ,
d a t a 1 1 [ s u b j e c t s 1 , ] [ , c ( 1 , 3 , 4 , 7 , 8 , 9 , 1 0 , 1 1 , 1 4 , 1 5 , 1 6 ,
1 7 , 1 8 , 1 9 , 2 0 , 2 2 , 2 3 , 2 4 , 2 5 ) ] )
n = dim ( d a t a 6 6 ) [ 1 ]
sum=0
f o r ( i i n 1 : n ){ sum=sum+(IPTW i v a r i a n c e 1 ( model11 , i p tw e s t i m a t e 1 ,
da ta11 , s u b j e c t s 1 , i ,
H be ta11 , E b e t a b e t a i n v e r s e 1 ) ) }
re turn ( ( 1 / ( n ˆ 2 ) ) *sum ˆ 2 ) # f i n a l IPTW e s t i m a t i o n v a r i a n c e
}
#IPTW ATE e s t i m a t i o n
IPTW ATE= f u n c t i o n ( da ta11 , s u b j e c t s 1 , model11 ){
d a t a 6 6 = d a t a 1 1 [ s u b j e c t s 1 , ] [ , 1 : 2 5 ]
Y= S t r o k e TIA outcome [ s u b j e c t s 1 ]
Z= T r a n s r a d i a l Approach [ s u b j e c t s 1 ]
e=model11 $ f i t t e d
n = dim ( d a t a 6 6 ) [ 1 ]
ATE= (1 / n ) *sum ( Z*Y / e ) − (1 / n ) *sum ( ( ( 1 −Z ) *Y) / (1− e ) )
re turn ( c (ATE ) )
}
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